<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Microorganisms</journal-id><journal-id journal-id-type="iso-abbrev">Microorganisms</journal-id><journal-id journal-id-type="pmc-domain-id">3054</journal-id><journal-id journal-id-type="pmc-domain">microorg</journal-id><journal-id journal-id-type="publisher-id">microorganisms</journal-id><journal-title-group><journal-title>Microorganisms</journal-title></journal-title-group><issn pub-type="epub">2076-2607</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12473099</article-id><article-id pub-id-type="pmcid-ver">PMC12473099.1</article-id><article-id pub-id-type="pmcaid">12473099</article-id><article-id pub-id-type="pmcaiid">12473099</article-id><article-id pub-id-type="pmid">41011460</article-id><article-id pub-id-type="doi">10.3390/microorganisms13092129</article-id><article-id pub-id-type="publisher-id">microorganisms-13-02129</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Autoimmune Skin Diseases in the Era of COVID-19: Pathophysiological Insights and Clinical Implications</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3936-8374</contrib-id><name name-style="western"><surname>Liakou</surname><given-names initials="AI">Aikaterini I.</given-names></name><xref rid="af1-microorganisms-13-02129" ref-type="aff">1</xref><xref rid="c1-microorganisms-13-02129" ref-type="corresp">*</xref><xref rid="fn1-microorganisms-13-02129" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0480-8520</contrib-id><name name-style="western"><surname>Routsi</surname><given-names initials="E">Eleni</given-names></name><xref rid="af1-microorganisms-13-02129" ref-type="aff">1</xref><xref rid="fn1-microorganisms-13-02129" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Plisioti</surname><given-names initials="K">Kalliopi</given-names></name><xref rid="af2-microorganisms-13-02129" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-2644-9489</contrib-id><name name-style="western"><surname>Tziona</surname><given-names initials="E">Eleni</given-names></name><xref rid="af3-microorganisms-13-02129" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7074-2374</contrib-id><name name-style="western"><surname>Koumaki</surname><given-names initials="D">Dimitra</given-names></name><xref rid="af4-microorganisms-13-02129" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kalamata</surname><given-names initials="M">Magdalini</given-names></name><xref rid="af1-microorganisms-13-02129" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bompou</surname><given-names initials="EK">Evangelia-Konstantina</given-names></name><xref rid="af1-microorganisms-13-02129" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9972-8901</contrib-id><name name-style="western"><surname>Sokou</surname><given-names initials="R">Rozeta</given-names></name><xref rid="af5-microorganisms-13-02129" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1082-5674</contrib-id><name name-style="western"><surname>Ioannou</surname><given-names initials="P">Petros</given-names></name><xref rid="af6-microorganisms-13-02129" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6102-6579</contrib-id><name name-style="western"><surname>Bonovas</surname><given-names initials="S">Stefanos</given-names></name><xref rid="af7-microorganisms-13-02129" ref-type="aff">7</xref><xref rid="af8-microorganisms-13-02129" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Samonis</surname><given-names initials="G">George</given-names></name><xref rid="af6-microorganisms-13-02129" ref-type="aff">6</xref><xref rid="af9-microorganisms-13-02129" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3695-0759</contrib-id><name name-style="western"><surname>Tsantes</surname><given-names initials="AG">Andreas G.</given-names></name><xref rid="af10-microorganisms-13-02129" ref-type="aff">10</xref><xref rid="af11-microorganisms-13-02129" ref-type="aff">11</xref><xref rid="c1-microorganisms-13-02129" ref-type="corresp">*</xref><xref rid="fn2-microorganisms-13-02129" ref-type="author-notes">&#8225;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stratigos</surname><given-names initials="A">Alexander</given-names></name><xref rid="af1-microorganisms-13-02129" ref-type="aff">1</xref><xref rid="fn2-microorganisms-13-02129" ref-type="author-notes">&#8225;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Oliveira</surname><given-names initials="EA">Eduardo Ara&#250;jo</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Sim&#245;es E Silva</surname><given-names initials="AC">Ana Cristina</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-microorganisms-13-02129"><label>1</label>1st Department of Dermatology and Venereology, &#8220;Andreas Syggros&#8221; Hospital for Skin Diseases, National &amp; Kapodistrian University of Athens Medical School, 16121 Athens, Greece; <email>routsie@gmail.com</email> (E.R.); <email>magda.kalamata@gmail.com</email> (M.K.); <email>valentina.bompou@gmail.com</email> (E.-K.B.); <email>alstrat2@gmail.com</email> (A.S.)</aff><aff id="af2-microorganisms-13-02129"><label>2</label>Faculty of Medicine and Pharmacy, &#8220;Dunarea de Jos&#8221; University of Galati, 800008 Galati, Romania; <email>kalliopi.plisioti@gmail.com</email></aff><aff id="af3-microorganisms-13-02129"><label>3</label>Aristotle University School of Medicine, 54124 Thessaloniki, Greece; <email>helentziona@gmail.com</email></aff><aff id="af4-microorganisms-13-02129"><label>4</label>Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece; <email>dkoumaki@yahoo.gr</email></aff><aff id="af5-microorganisms-13-02129"><label>5</label>Neonatal Department, Aretaio Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece; <email>sokourozeta@yahoo.gr</email></aff><aff id="af6-microorganisms-13-02129"><label>6</label>School of Medicine, University of Crete, 71003 Heraklion, Greece<email>samonis@med.uoc.gr</email> (G.S.)</aff><aff id="af7-microorganisms-13-02129"><label>7</label>Department of Biomedical Sciences, Humanitas University, Pieve Emuanuele, 20072 Milan, Italy; <email>sbonovas@gmail.com</email></aff><aff id="af8-microorganisms-13-02129"><label>8</label>IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy</aff><aff id="af9-microorganisms-13-02129"><label>9</label>1st Oncology Department Metropolitan Hospital, Neon Faliron, 18547 Athens, Greece</aff><aff id="af10-microorganisms-13-02129"><label>10</label>Laboratory of Hematology and Blood Bank Unit, &#8220;Attikon&#8221; University Hospital, School of Medicine, National and Kapodistrian University, 12462 Athens, Greece</aff><aff id="af11-microorganisms-13-02129"><label>11</label>Microbiology Department, &#8220;Saint Savvas&#8221; Oncology Hospital, 11522 Athens, Greece</aff><author-notes><corresp id="c1-microorganisms-13-02129"><label>*</label>Correspondence: <email>a.i.liakou@gmail.com</email> (A.I.L.); <email>andreas.tsantes@yahoo.com</email> (A.G.T.)</corresp><fn id="fn1-microorganisms-13-02129"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn><fn id="fn2-microorganisms-13-02129"><label>&#8225;</label><p>These authors also contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>13</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496716</issue-id><elocation-id>2129</elocation-id><history><date date-type="received"><day>08</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>02</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="microorganisms-13-02129.pdf"/><abstract><p>The COVID-19 pandemic has highlighted intricate associations between SARS-CoV-2 infection and autoimmune skin diseases (ASDs). This review examines the bidirectional relationship between COVID-19 and ASDs including hidradenitis suppurativa, psoriasis, atopic dermatitis, alopecia areata, autoimmune bullous diseases, cutaneous and systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and lichen planus. Current evidence indicates that SARS-CoV-2 may precipitate or worsen ASDs via mechanisms such as molecular mimicry, dysregulated cytokine signaling, and enhanced Th1/Th17 immune responses, leading to loss of self-tolerance and autoantibody production. Epidemiological studies have identified increased incidence and flares of psoriasis, hidradenitis suppurativa, and other ASDs following both COVID-19 infection and vaccination, with mRNA vaccines associated with a higher risk of flare in hidradenitis suppurativa compared with non-mRNA vaccines. Notably, severe COVID-19 is associated with a greater risk of new-onset autoimmune disease, and patients with pre-existing inflammatory skin conditions may have increased susceptibility to SARS-CoV-2 infection but experience less severe COVID-19 courses. These findings underscore the need for ongoing surveillance and mechanistic studies to clarify the immunopathogenic links between SARS-CoV-2 and ASDs and inform management strategies for affected patients in the context of both infection and vaccination.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>autoimmune skin diseases</kwd><kwd>hidradenitis suppurativa</kwd><kwd>psoriasis</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-microorganisms-13-02129"><title>1. Introduction</title><p>From the start of the outbreak, several reports appeared on the autoimmune manifestations and autoimmune sequelae of Coronavirus Disease-2019 (COVID-19) infection [<xref rid="B1-microorganisms-13-02129" ref-type="bibr">1</xref>]. The COVID-19 pandemic has brought unprecedented challenges to healthcare systems globally, not only due to the acute effects of SARS-CoV-2 infection, but also because of its broader immunological consequences. Increasing evidence suggests that COVID-19 can act as a trigger or modulator of autoimmune phenomena. Autoimmune skin diseases (ASDs), including psoriasis, hidradenitis suppurativa (HS), atopic dermatitis (AD), and alopecia areata, have shown variable responses during the pandemic, ranging from disease exacerbation to new-onset presentations. Potential mechanisms include direct viral effects, molecular mimicry, dysregulated cytokine responses, and psychological stress. Moreover, the widespread use of immunomodulatory therapies and the introduction of COVID-19 vaccines have raised questions about the safety, efficacy, and impact of these interventions in patients with preexisting or newly emerging ASDs [<xref rid="B2-microorganisms-13-02129" ref-type="bibr">2</xref>]. Despite the growing body of literature, the relationship between COVID-19 and ASDs remains incompletely understood. Current reports are fragmented, and the findings are sometimes conflicting, particularly regarding the bidirectional effects of infection and treatment. A comprehensive synthesis is therefore needed to clarify the clinical patterns, pathophysiological mechanisms, and therapeutic implications. This review aims to summarize the available evidence on the interplay between COVID-19 and autoimmune skin diseases, highlight emerging pathophysiologic insights, and discuss implications for clinical management and vaccination strategies.</p></sec><sec id="sec2-microorganisms-13-02129"><title>2. Hidradenitis Suppurativa</title><p>The COVID-19 pandemic has significantly impacted the management and progression of chronic inflammatory skin diseases, notably HS. HS is a chronic inflammatory skin disorder characterized by painful nodules, abscesses, and sinus tracts, primarily affecting intertriginous areas. The pathogenesis of HS involves immune dysregulation, with elevated levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-&#945;) and interleukin-17 (IL-17) [<xref rid="B3-microorganisms-13-02129" ref-type="bibr">3</xref>,<xref rid="B4-microorganisms-13-02129" ref-type="bibr">4</xref>,<xref rid="B5-microorganisms-13-02129" ref-type="bibr">5</xref>].</p><p>The relationship between COVID-19 infection and HS disease activity has been a subject of investigation. Although the exact mechanisms associated between COVID-19 and flares in autoimmune skin diseases remain unclear, viral infections can exacerbate autoimmunity through molecular mimicry, bystander activation, and persistent immune dysregulation. Cytokines such as TNF-&#945;, IL-17, and IL-23 drive inflammation in HS patients, with COVID-19 infection potentially enhancing this response through increased IL-1&#946; production, IL-17 activation, and inflammasome activation [<xref rid="B6-microorganisms-13-02129" ref-type="bibr">6</xref>,<xref rid="B7-microorganisms-13-02129" ref-type="bibr">7</xref>,<xref rid="B8-microorganisms-13-02129" ref-type="bibr">8</xref>]. COVID-19-induced cytokine release syndrome, marked by excessive interleukin and TNF-&#945; secretion, may disrupt immune homeostasis, triggering disease exacerbation [<xref rid="B9-microorganisms-13-02129" ref-type="bibr">9</xref>,<xref rid="B10-microorganisms-13-02129" ref-type="bibr">10</xref>,<xref rid="B11-microorganisms-13-02129" ref-type="bibr">11</xref>,<xref rid="B12-microorganisms-13-02129" ref-type="bibr">12</xref>]. Moreover, limited access to healthcare services during lockdowns led to delays in diagnosis and treatment, adversely affecting disease control. Additionally, lifestyle changes such as reduced physical activity and dietary alterations contributed to weight gain, potentially exacerbating HS severity. A study highlighted that decreased physical activity during lockdowns increased the obesity rates, a known exacerbating factor for HS [<xref rid="B13-microorganisms-13-02129" ref-type="bibr">13</xref>]. Another study reported that while most HS patients infected with COVID-19 experienced no change in disease activity, approximately 18.8% noted a marked increase in pain and the development of new inflammatory lesions during infection. These findings suggest that COVID-19 may exacerbate HS in a subset of patients, potentially due to the systemic inflammatory response triggered by the virus [<xref rid="B14-microorganisms-13-02129" ref-type="bibr">14</xref>].</p><p>The management of biologic treatments in patients with COVID-19 has been debated due to concerns about the potential negative effects on infection progression. COVID-19 follows a biphasic course, beginning with an antiviral phase and transitioning to a hyperinflammatory state. Cytokines like TNF-&#945;, IL-1, and IL-6 dominate the inflammatory phase, while IL-15, interferons, and other cytokines are crucial for viral clearance. These pathways suggest that anti-TNF-&#945; and anti-IL-17 therapies may not directly impair antiviral responses. Clinical guidance on the continuation or discontinuation of biologics should be individualized and is supported by phase 3 trials showing no increased infection risk in HS patients treated with adalimumab [<xref rid="B15-microorganisms-13-02129" ref-type="bibr">15</xref>,<xref rid="B16-microorganisms-13-02129" ref-type="bibr">16</xref>,<xref rid="B17-microorganisms-13-02129" ref-type="bibr">17</xref>].</p><p>Regarding COVID-19 susceptibility, the current evidence does not indicate that HS inherently increases the risk of contracting SARS-CoV-2. However, concerns have been raised regarding whether HS itself predisposes patients to more severe COVID-19 outcomes. A retrospective study compared HS patients who contracted COVID-19 with non-HS COVID-19 patients [<xref rid="B18-microorganisms-13-02129" ref-type="bibr">18</xref>]. The study found that HS patients who contracted COVID-19 were significantly more likely to experience complications (35% vs. 7%; <italic toggle="yes">p</italic> = 0.001) and require COVID-19 treatment (37% vs. 7%; <italic toggle="yes">p</italic> = 0.0001) compared with non-HS COVID-19 patients. However, it is important to note that HS patients often have comorbidities such as obesity and cardiovascular disease, which are established risk factors for severe COVID-19. Therefore, the presence of these comorbidities, rather than HS itself, may contribute to increased risk.</p><p>Although the introduction of COVID-19 vaccines has been pivotal in controlling the pandemic, there have been reports of HS exacerbations following vaccination. Recent studies have investigated the impact of COVID-19 vaccination on HS, raising questions about safety and potential disease exacerbation. In a retrospective study of 250 vaccinated HS patients, mRNA vaccines were associated with a higher risk of post-vaccination flares compared with non-mRNA vaccines [<xref rid="B19-microorganisms-13-02129" ref-type="bibr">19</xref>,<xref rid="B20-microorganisms-13-02129" ref-type="bibr">20</xref>]. However, as this was a single-center study with a limited sample size, the findings should be interpreted with caution and require confirmation in larger cohorts. Notably, HS patients on biologic therapy were less likely to develop flares post-vaccination, suggesting a protective role of biologics. A small case series, including reports by Martora et al. and Alexander et al., described HS exacerbations post-vaccination. However, the authors of both studies concluded that these flares did not justify contraindicating further doses [<xref rid="B21-microorganisms-13-02129" ref-type="bibr">21</xref>,<xref rid="B22-microorganisms-13-02129" ref-type="bibr">22</xref>]. Larger studies, such as a multicenter retrospective cohort by Pakhchanian et al., found no significant increase in vaccine-related adverse events among HS patients, even those on systemic therapy. Clinicians should monitor patients for potential flares and optimize disease management pre- and post-vaccination. Further epidemiological and mechanistic studies are needed to clarify the relationship between COVID-19 vaccination and HS [<xref rid="B23-microorganisms-13-02129" ref-type="bibr">23</xref>].</p><p>While data specific to HS are limited, extrapolation from other inflammatory conditions suggests that patients on biologic therapies can mount adequate immune responses to vaccines. Consultation with healthcare providers is essential to determine the optimal timing of vaccination, especially concerning ongoing immunosuppressive treatments. Ongoing research and patient registries, such as the Global HS COVID-19 Registry, are essential in deepening our understanding and guiding management strategies for HS patients during this unprecedented time [<xref rid="B24-microorganisms-13-02129" ref-type="bibr">24</xref>,<xref rid="B25-microorganisms-13-02129" ref-type="bibr">25</xref>,<xref rid="B26-microorganisms-13-02129" ref-type="bibr">26</xref>].</p></sec><sec id="sec3-microorganisms-13-02129"><title>3. Psoriasis</title><p>Psoriasis is a chronic autoimmune skin disorder characterized by the hyperproliferation of keratinocytes and systemic inflammation. The COVID-19 pandemic has introduced complexities in managing psoriatic patients, particularly concerning the interplay between the disease, its treatments, and SARS-CoV-2 infection [<xref rid="B27-microorganisms-13-02129" ref-type="bibr">27</xref>,<xref rid="B28-microorganisms-13-02129" ref-type="bibr">28</xref>,<xref rid="B29-microorganisms-13-02129" ref-type="bibr">29</xref>].</p><p>Emerging evidence suggests that COVID-19 infection may act as a triggering factor for psoriasis exacerbations, likely through the dysregulation of immune pathways implicated in the disease. The relationship between psoriasis and COVID-19 is multifaceted. &#921;n psoriasis, the Th17-driven inflammatory response, characterized by elevated levels of IL-23, IL-17, and TNF-&#945;, is amplified during COVID-19 infection, triggering disease flares [<xref rid="B30-microorganisms-13-02129" ref-type="bibr">30</xref>,<xref rid="B31-microorganisms-13-02129" ref-type="bibr">31</xref>,<xref rid="B32-microorganisms-13-02129" ref-type="bibr">32</xref>]. Psoriasis flares in the context of COVID-19 infection are primarily attributed to the virus-induced hyperinflammatory state, commonly referred to as a &#8220;cytokine storm&#8221;. COVID-19 infection leads to the excessive production of pro-inflammatory cytokines, including ILs and TNF-&#945;, which are pivotal in the pathogenesis of psoriasis. This overproduction can disrupt the delicate immune balance, potentially triggering or exacerbating psoriatic lesions. Additionally, the binding of the SARS-CoV-2 spike protein to the ACE2 receptor results in its downregulation, leading to increased levels of angiotensin II. Elevated angiotensin II can further promote inflammation, contributing to psoriatic flare-ups. Moreover, the systemic inflammation associated with COVID-19 may amplify the availability of self-antigens through mechanisms like antigen mimicry and epitope spreading, further fueling psoriatic disease activity. Moreover, the psychological impact of the pandemic on psoriatic patients has also been significant. Stress is a well-known trigger for psoriasis exacerbations, and the global crisis has undoubtedly heightened the stress levels among individuals [<xref rid="B29-microorganisms-13-02129" ref-type="bibr">29</xref>,<xref rid="B33-microorganisms-13-02129" ref-type="bibr">33</xref>,<xref rid="B34-microorganisms-13-02129" ref-type="bibr">34</xref>]. Several case reports have documented post-COVID-19 flares of psoriasis including guttate, pustular, and severe plaque variants [<xref rid="B35-microorganisms-13-02129" ref-type="bibr">35</xref>,<xref rid="B36-microorganisms-13-02129" ref-type="bibr">36</xref>,<xref rid="B37-microorganisms-13-02129" ref-type="bibr">37</xref>,<xref rid="B38-microorganisms-13-02129" ref-type="bibr">38</xref>,<xref rid="B39-microorganisms-13-02129" ref-type="bibr">39</xref>]. Although current data are limited to individual case observations, these findings underscore the need for heightened clinical awareness and further investigation into the immunological interplay between COVID-19 and chronic inflammatory dermatoses such as psoriasis [<xref rid="B39-microorganisms-13-02129" ref-type="bibr">39</xref>].</p><p>The management of psoriasis during the pandemic has seen varied approaches. Notably, studies reported that teledermatology services effectively managed psoriasis patients, reducing the need for face-to-face consultations and thereby minimizing potential exposure to the virus. This approach not only ensured continuity of care, but also maintained high patient satisfaction and compliance. Teledermatology emerged as an important tool for psoriasis care, ensuring the continuity of treatment and minimizing exposure risks. Studies reported high patient satisfaction, improved treatment adherence, and reduced need for in-person visits [<xref rid="B40-microorganisms-13-02129" ref-type="bibr">40</xref>,<xref rid="B41-microorganisms-13-02129" ref-type="bibr">41</xref>,<xref rid="B42-microorganisms-13-02129" ref-type="bibr">42</xref>,<xref rid="B43-microorganisms-13-02129" ref-type="bibr">43</xref>]. However, limitations included uneven access to technology and challenges in assessing subtle clinical changes remotely. In many cases, the COVID-19 pandemic led to treatment disruptions due to concerns about immunosuppression, prompting some individuals to discontinue or delay biologic therapies, potentially leading to disease flares. While initial fears prompted treatment interruptions, accumulating evidence suggests that biologics targeting IL-17 and IL-23 do not increase COVID-19 severity. Observational studies and registry data have reported no higher rates of infection or adverse outcomes among psoriasis patients receiving biologics compared with those not on systemic therapy [<xref rid="B40-microorganisms-13-02129" ref-type="bibr">40</xref>]. Nonetheless, the evidence is largely derived from observational cohorts, and randomized trial data remain lacking. Therefore, many patients and clinicians opted to continue biologic therapies, given the lack of definitive evidence linking these treatments to increased COVID-19 severity. Based on the current literature, the continuation of biological therapy under medical supervision is advised, balancing the benefits of disease control against potential infection risks [<xref rid="B40-microorganisms-13-02129" ref-type="bibr">40</xref>].</p><p>Early in the pandemic, concerns arose regarding the susceptibility of psoriatic patients to COVID-19, especially those on immunomodulatory therapies. However, accumulating evidence suggests that psoriasis itself does not inherently increase the risk of contracting COVID-19. Instead, comorbidities frequently associated with psoriasis, such as obesity, diabetes, and cardiovascular diseases, have been identified as significant risk factors for severe COVID-19 outcomes [<xref rid="B27-microorganisms-13-02129" ref-type="bibr">27</xref>,<xref rid="B28-microorganisms-13-02129" ref-type="bibr">28</xref>]. A study indicated that among psoriasis patients infected with SARS-CoV-2, 5.8% required hospitalization, and 23.6% experienced psoriasis exacerbation due to the infection [<xref rid="B29-microorganisms-13-02129" ref-type="bibr">29</xref>].</p><p>Vaccination against COVID-19 has been a pivotal strategy in controlling the pandemic. For psoriatic patients, concerns regarding vaccine efficacy and potential disease flares post-vaccination have been prevalent. Current evidence indicates that mRNA COVID-19 vaccines are safe for individuals with psoriasis including those on immunomodulatory therapies [<xref rid="B44-microorganisms-13-02129" ref-type="bibr">44</xref>].</p><p>The psychological impact of the pandemic on psoriatic patients has also been significant. Stress is a well-known trigger for psoriasis exacerbations, and the global crisis has undoubtedly heightened stress levels among individuals. A study conducted in Denmark highlighted that individual with psoriasis experienced worsened mental well-being during the pandemic compared with healthy individuals, underscoring the need for holistic patient care that addresses both physical and psychological health [<xref rid="B45-microorganisms-13-02129" ref-type="bibr">45</xref>]. </p></sec><sec id="sec4-microorganisms-13-02129"><title>4. Atopic Dermatitis</title><p>The relationship between COVID-19 infection and AD remains complex. AD is a chronic inflammatory condition resulting from a combination of skin barrier dysfunction and immune dysregulation. Two main theories explain its pathogenesis: the &#8220;outside-in&#8221; hypothesis, which suggests that environmental allergens initiate the disease by weakening the skin barrier and promoting IgE sensitization, and the &#8220;inside-out&#8221; hypothesis, which proposes that genetic factors&#8212;most notably mutations in the filaggrin (FLG) gene&#8212;lead to impaired barrier function and subsequent immune activation. During the COVID-19 pandemic, AD flares have been reported more frequently, likely due to enhanced type 2 cytokine activity (IL-4, IL-13, IL-31), increased psychological stress, and repetitive hand hygiene practices that further compromise the skin. Exacerbations may be managed with topical corticosteroids, while systemic treatments such as JAK inhibitors are considered for more severe or persistent disease [<xref rid="B46-microorganisms-13-02129" ref-type="bibr">46</xref>,<xref rid="B47-microorganisms-13-02129" ref-type="bibr">47</xref>]. Skin biopsies from AD patients also show a predominance of Th2-derived cytokines including IL-4 and IL-13, implicated in pathogenesis [<xref rid="B48-microorganisms-13-02129" ref-type="bibr">48</xref>]. The Th2/Th1 imbalance observed in AD, which promotes IgE-mediated hypersensitivity, may be disrupted by COVID-19 infection, leading to AD exacerbations [<xref rid="B49-microorganisms-13-02129" ref-type="bibr">49</xref>,<xref rid="B50-microorganisms-13-02129" ref-type="bibr">50</xref>]. In an investigation conducted in the Netherlands, 26% of the participants with AD reported a deterioration in symptoms during active COVID-19 infection [<xref rid="B51-microorganisms-13-02129" ref-type="bibr">51</xref>]. Another study revealed that 43% of AD patients experienced disease flare-ups post-COVID-19, with many requiring treatment adjustments. Interestingly, exacerbation in patients receiving immunosuppressives was less pronounced, possibly due to the protective benefits of these drugs against virus-induced inflammatory cascades [<xref rid="B47-microorganisms-13-02129" ref-type="bibr">47</xref>,<xref rid="B52-microorganisms-13-02129" ref-type="bibr">52</xref>,<xref rid="B53-microorganisms-13-02129" ref-type="bibr">53</xref>,<xref rid="B54-microorganisms-13-02129" ref-type="bibr">54</xref>,<xref rid="B55-microorganisms-13-02129" ref-type="bibr">55</xref>]. Epidemiological evidence further supports a potential link between COVID-19 and new-onset AD. A retrospective study reported that individuals with a history of SARS-CoV-2 infection had a 33% higher likelihood of developing AD compared with matched controls [<xref rid="B54-microorganisms-13-02129" ref-type="bibr">54</xref>]. However, this study relied on registry data and lacked long-term follow-up, so the findings should be interpreted with caution.</p><p>In conclusion, COVID-19 may exacerbate AD through several interrelated mechanisms, including heightened type 2 cytokine activity (IL-4, IL-13, IL-31), skin barrier impairment from repetitive hand hygiene practices, and increased psychological stress, all of which converge to disrupt immune homeostasis and promote disease flares.</p></sec><sec id="sec5-microorganisms-13-02129"><title>5. Alopecia Areata</title><p>Recent research has explored the link between COVID-19 and alopecia areata (AA), revealing that the virus may act as a catalyst for the onset or exacerbation of the condition. The exact mechanisms linking COVID-19 to AA remain under investigation. The current mechanism of AA is not clear. From a biological perspective, SARS-CoV-2 infection may exacerbate or trigger AA through IFN-mediated antiviral responses that disrupt hair follicle immune privilege, upregulate MHC class I expression, and activate pro-inflammatory cytokines such as IL-6 [<xref rid="B56-microorganisms-13-02129" ref-type="bibr">56</xref>]. In parallel, psychological stress, which was pervasive during the pandemic, may act as an additional aggravating factor. Stress is known to influence immune responses and exacerbate autoimmune conditions and therefore may contribute independently or synergistically to AA flares during the COVID-19 era [<xref rid="B57-microorganisms-13-02129" ref-type="bibr">57</xref>,<xref rid="B58-microorganisms-13-02129" ref-type="bibr">58</xref>]. The systemic inflammatory response caused by the virus could also provide a potential and plausible explanation [<xref rid="B59-microorganisms-13-02129" ref-type="bibr">59</xref>].</p><p>COVID-19 has been shown to affect AA recurrence, as higher relapse rates (44%) were noted among those who contracted SARS-CoV-2 compared with the control group (12%) [<xref rid="B60-microorganisms-13-02129" ref-type="bibr">60</xref>]. Other data support that individuals developed AA 1 to 2 months after infection from COVID-19, suggesting an association between infection and disease emergence [<xref rid="B61-microorganisms-13-02129" ref-type="bibr">61</xref>]. Epidemiological studies also support this association. For instance, large-scale research in South Korea found an increased incidence of AA among individuals who had recovered from COVID-19 [<xref rid="B58-microorganisms-13-02129" ref-type="bibr">58</xref>]. Another large retrospective cohort highlighted that this correlation of disease incidence was also tightly interconnected to the severity of COVID-19 [<xref rid="B62-microorganisms-13-02129" ref-type="bibr">62</xref>,<xref rid="B63-microorganisms-13-02129" ref-type="bibr">63</xref>]. While these findings are compelling, the relationship between COVID-19 and AA remains complex, and for the most part unknown. It is important to note that the majority of available evidence consists of case reports and retrospective cohorts, which may be subject to publication bias. While emerging data suggest a possible link between COVID-19 and AA, this relationship remains complex and is not yet fully elucidated. Larger, prospective studies are needed to disentangle the biological effects of SARS-CoV-2 infection from psychological stressors and to minimize the influence of publication bias inherent in early reports. Unraveling this connection in the post-COVID-19 era, when our information and understanding of both entities increases, could significantly improve the management of AA in patients affected by COVID-19. The delineation of the relationship between COVID-19 and AA could provide insights into how viral infections impact autoimmune diseases.</p></sec><sec id="sec6-microorganisms-13-02129"><title>6. Autoimmune Bullous Diseases</title><p>Autoimmune bullous diseases (AIBDs), such as pemphigus vulgaris and bullous pemphigoid, arise when autoantibodies target structural proteins in the skin, leading to blister formation. Emerging data suggest that SARS-CoV-2 infection can trigger or worsen AIBDs through immune dysregulation: viral-induced cytokine release and molecular mimicry between viral peptides and skin antigens&#8212;as evidenced by shared epitope sequences with bullous pemphigoid&#8212;may provoke autoantibody production [<xref rid="B64-microorganisms-13-02129" ref-type="bibr">64</xref>]. Several case reports have reported that in patients with pre-existing pemphigus or bullous pemphigoid, the onset of COVID-19 has been associated with flare-ups or new cases [<xref rid="B61-microorganisms-13-02129" ref-type="bibr">61</xref>,<xref rid="B65-microorganisms-13-02129" ref-type="bibr">65</xref>]. The immune system&#8217;s heightened inflammatory response during COVID-19 infection may contribute to the worsening of these conditions, as it can potentially activate autoimmune mechanisms, leading to the breakdown of skin structures that result in antigen shedding, immune activation, and ultimately blister formation and manifestation of the clinical entities of autoimmune bullous disease of the skin [<xref rid="B66-microorganisms-13-02129" ref-type="bibr">66</xref>]. In addition to the above, the use of corticosteroids and other immunosuppressive medications (e.g., CD20-directed agents) commonly prescribed to manage severe pemphigus, and bullous pemphigoid may further complicate the management of COVID-19 infection [<xref rid="B67-microorganisms-13-02129" ref-type="bibr">67</xref>]. B-cell depletion and subsequent humoral immunity impairment make patients highly susceptible to a broad range of infections, including COVID-19, and possibly influence the severity of the disease course [<xref rid="B68-microorganisms-13-02129" ref-type="bibr">68</xref>]. Current expert guidance suggests that abrupt discontinuation of immunosuppressive therapy in patients with AIBDs should generally be avoided, as uncontrolled disease activity may itself increase morbidity. Instead, therapy should be tailored individually: patients on systemic corticosteroids may require careful dose adjustments, while those on B-cell&#8211;depleting agents such as rituximab should be closely monitored, with the consideration of delaying treatment in stable disease during active SARS-CoV-2 infection [<xref rid="B68-microorganisms-13-02129" ref-type="bibr">68</xref>]. This has been documented in clinical evidence supporting that patients on long-term immunosuppressive therapy for autoimmune blistering diseases may experience more severe COVID-19 infection [<xref rid="B69-microorganisms-13-02129" ref-type="bibr">69</xref>]. It should be noted that the majority of current evidence derives from case reports and small retrospective studies, which are inherently subject to publication bias and limited generalizability. As a result, the association between COVID-19 and AIBDs should be interpreted with caution until supported by larger prospective studies.</p></sec><sec id="sec7-microorganisms-13-02129"><title>7. Cutaneous and Systemic Lupus Erythematosus</title><p>Cutaneous lupus erythematosus (CLE) encompasses autoimmune skin disorders that can be influenced by various environmental factors including viral infections. Emerging evidence suggests a correlation between SARS-CoV-2 infection and the onset or exacerbation of CLE [<xref rid="B70-microorganisms-13-02129" ref-type="bibr">70</xref>]. Although SARS-CoV-2 has been associated with the induction of autoantibodies such as ANA, lupus anticoagulant, and anti-Ro/SSA in some reports, these findings remain preliminary and do not establish a direct pathogenic link to lupus or systemic sclerosis. The proposed mechanisms should therefore be interpreted as speculative hypotheses rather than confirmed pathways [<xref rid="B71-microorganisms-13-02129" ref-type="bibr">71</xref>,<xref rid="B72-microorganisms-13-02129" ref-type="bibr">72</xref>].</p><p>A few case reports have described an association between COVID-19 and CLE. A 67-year-old woman with pre-existing CLE developed a Rowell syndrome-like flare approximately two weeks after contracting SARS-CoV-2 [<xref rid="B73-microorganisms-13-02129" ref-type="bibr">73</xref>]. Another case report presented a patient with a rare variant of CLE, namely lupus panniculitis, as the primary manifestation of SLE stimulated by COVID-19 infection [<xref rid="B74-microorganisms-13-02129" ref-type="bibr">74</xref>]. Although the clinical relevance of this evidence remains limited, the association between LE and COVID-19 is expected to be further delineated as our knowledge and experience with the virus expands. Overall, while case reports suggest a possible association between COVID-19 and lupus manifestations, the evidence remains anecdotal, and mechanistic explanations are speculative. More robust studies are needed to determine whether SARS-CoV-2 acts as a true disease trigger or whether the observed associations reflect coincidental findings.</p></sec><sec id="sec8-microorganisms-13-02129"><title>8. Systemic Sclerosis</title><p>There have been reports of new-onset SSc following COVID-19 infection. SS, defined by progressive fibrosis and vascular dysfunction, parallels COVID-19-related endothelial injury and hyperinflammation [<xref rid="B75-microorganisms-13-02129" ref-type="bibr">75</xref>,<xref rid="B76-microorganisms-13-02129" ref-type="bibr">76</xref>]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection could thus accelerate fibrotic processes, contributing to worsened outcomes in SSc patients [<xref rid="B77-microorganisms-13-02129" ref-type="bibr">77</xref>]. Interestingly, a case report described a female patient who developed systemic sclerosis after COVID-19 infection, highlighting the potential for SARS-CoV-2 to trigger autoimmune responses leading to SSc development. Additionally, the SARS-CoV-2 spike protein has been found to accelerate systemic sclerosis by promoting fibrosis through the upregulation of pathways involved in inflammatory responses and autoantibody formation and secretion [<xref rid="B78-microorganisms-13-02129" ref-type="bibr">78</xref>]. A major SSc complication is interstitial lung disease (ILD). Therefore, ILD could potentially predispose SSc patients to severe COVID-19 infection associated with poor outcomes [<xref rid="B78-microorganisms-13-02129" ref-type="bibr">78</xref>]. Additionally, considering the concomitant use of immunosuppressive therapies in severe SSc, the risk could increase even more [<xref rid="B75-microorganisms-13-02129" ref-type="bibr">75</xref>]. COVID-19 can cause severe pneumonia with radiological features of interstitial fibrosis, similar to ILD secondary to SSc, thereby complicating the clinical scenario by presenting a unique challenge in differential diagnosis between the two [<xref rid="B79-microorganisms-13-02129" ref-type="bibr">79</xref>].</p></sec><sec id="sec9-microorganisms-13-02129"><title>9. Dermatomyositis</title><p>Dermatomyositis (DM) is a systemic autoimmune disease characterized by skin manifestations and proximal muscle weakness, with COVID-19 increasingly reported as a potential trigger for both new-onset disease and flares of pre-existing DM. Evidence remains limited and largely anecdotal. For example, single case reports describe new-onset DM following SARS-CoV-2 infection and flare-ups in young patients after even mild COVID-19 illness [<xref rid="B80-microorganisms-13-02129" ref-type="bibr">80</xref>,<xref rid="B81-microorganisms-13-02129" ref-type="bibr">81</xref>]. While these reports suggest a possible association, the reliance on case-based data limits generalizability and may be influenced by publication bias.</p><p>Mechanistically, autoantibodies play a central role. Notably, <italic toggle="yes">anti-melanoma differentiation-associated gene 5</italic> (MDA5) antibodies, which are linked to severe forms of DM with interstitial lung disease, have also been associated with worse COVID-19 outcomes and increased mortality [<xref rid="B82-microorganisms-13-02129" ref-type="bibr">82</xref>]. The management of DM during the COVID-19 pandemic requires balancing immunosuppression with infection risk. Data suggest that maintaining disease control is critical, as uncontrolled DM poses greater risks than potential viral complications. Corticosteroids should be used at the lowest effective dose, and steroid-sparing immunosuppressive agents (e.g., methotrexate, azathioprine, mycophenolate mofetil) may be considered [<xref rid="B83-microorganisms-13-02129" ref-type="bibr">83</xref>]. B-cell depleting therapies and high-dose corticosteroids should be used with caution, particularly in patients at high risk for severe COVID-19. Vaccination and preventive measures remain essential adjuncts to care [<xref rid="B83-microorganisms-13-02129" ref-type="bibr">83</xref>]. Further research is needed to provide more insights into the optimal management strategies for DM patients amidst the pandemic.</p></sec><sec id="sec10-microorganisms-13-02129"><title>10. Lichen Planus</title><p>Lichen planus (LP) is a group of chronic inflammatory diseases that mainly affect middle-aged adults. While LP primarily includes skin and oral mucosa, other mucous membranes and skin appendages, such as nails and hair, can also be damaged [<xref rid="B83-microorganisms-13-02129" ref-type="bibr">83</xref>,<xref rid="B84-microorganisms-13-02129" ref-type="bibr">84</xref>,<xref rid="B85-microorganisms-13-02129" ref-type="bibr">85</xref>,<xref rid="B86-microorganisms-13-02129" ref-type="bibr">86</xref>,<xref rid="B87-microorganisms-13-02129" ref-type="bibr">87</xref>]. LP is increasingly considered a T cell-mediated autoimmune condition in which cytotoxic CD8+ T cells induce basal keratinocyte apoptosis, producing the characteristic interface dermatitis [<xref rid="B88-microorganisms-13-02129" ref-type="bibr">88</xref>,<xref rid="B89-microorganisms-13-02129" ref-type="bibr">89</xref>,<xref rid="B90-microorganisms-13-02129" ref-type="bibr">90</xref>]. Although the exact etiology remains unclear, both infectious triggers (e.g., herpes simplex, varicella zoster, HPV-16) and immune dysregulation have been implicated [<xref rid="B90-microorganisms-13-02129" ref-type="bibr">90</xref>,<xref rid="B91-microorganisms-13-02129" ref-type="bibr">91</xref>,<xref rid="B92-microorganisms-13-02129" ref-type="bibr">92</xref>]. However, the precise relationship between viruses and LP remains an area of ongoing research.</p><p>In the context of COVID-19, several overlapping immunological pathways may contribute to LP pathogenesis. SARS-CoV-2 infection stimulates robust Th1 and Th17 immune responses and cytotoxic CD8+ T-cell activity, all of which can promote keratinocyte apoptosis, a hallmark of LP [<xref rid="B93-microorganisms-13-02129" ref-type="bibr">93</xref>,<xref rid="B94-microorganisms-13-02129" ref-type="bibr">94</xref>,<xref rid="B95-microorganisms-13-02129" ref-type="bibr">95</xref>,<xref rid="B96-microorganisms-13-02129" ref-type="bibr">96</xref>,<xref rid="B97-microorganisms-13-02129" ref-type="bibr">97</xref>,<xref rid="B98-microorganisms-13-02129" ref-type="bibr">98</xref>]. Molecular mimicry between SARS-CoV-2 antigens and epidermal self-antigens may further drive autoimmune cytotoxicity [<xref rid="B92-microorganisms-13-02129" ref-type="bibr">92</xref>,<xref rid="B99-microorganisms-13-02129" ref-type="bibr">99</xref>,<xref rid="B100-microorganisms-13-02129" ref-type="bibr">100</xref>]. Additionally, ACE2 receptors expressed in keratinocytes and oral mucosal cells provide a potential portal for viral interaction, amplifying local inflammation [<xref rid="B101-microorganisms-13-02129" ref-type="bibr">101</xref>,<xref rid="B102-microorganisms-13-02129" ref-type="bibr">102</xref>,<xref rid="B103-microorganisms-13-02129" ref-type="bibr">103</xref>]. Together, these mechanisms suggest that SARS-CoV-2 infection could act as a trigger for LP in genetically or immunologically predisposed individuals, though definitive causal links remain unproven. Another hypothesis is that molecular mimicry is responsible for triggering the autoimmune cytotoxic T cell (CTL) and Th1 responses that mediate LP in COVID-19 infection [<xref rid="B92-microorganisms-13-02129" ref-type="bibr">92</xref>,<xref rid="B100-microorganisms-13-02129" ref-type="bibr">100</xref>]. The SARS-CoV-2 antigen has demonstrated cross-reactivity with multiple endogenous human antigens including those found on the basal keratinocytes of the epidermis. Another important consideration is that the role of ACE2 receptors for host cell entry may be implicated, as these receptors are abundant in cells of the skin and oral mucosa. The binding of the SARS-CoV-2 spike protein to ACE2 receptors on epidermal cells may trigger Th1 recruitment and the subsequent autoimmune cascade responsible for LP pathogenesis in infection with SARS-CoV-2 [<xref rid="B101-microorganisms-13-02129" ref-type="bibr">101</xref>,<xref rid="B102-microorganisms-13-02129" ref-type="bibr">102</xref>,<xref rid="B103-microorganisms-13-02129" ref-type="bibr">103</xref>].</p><p>Clinically, sporadic reports describe both new-onset and exacerbations of LP after COVID-19 infection [<xref rid="B96-microorganisms-13-02129" ref-type="bibr">96</xref>]. Interestingly, more cases have been documented following COVID-19 vaccination, though these remain rare and are primarily limited to case reports and small series [<xref rid="B97-microorganisms-13-02129" ref-type="bibr">97</xref>]. Given the scale of the global vaccination efforts, the absolute risk appears extremely low, and causality has not been established. Current evidence therefore does not alter existing vaccination recommendations, which remain strongly favorable for patients with chronic inflammatory diseases.</p><p>Finally, there are concerns that immunocompromising comorbidities, including hypertension, diabetes and vitamin D deficiency, are risk factors that may increase susceptibility to LP after COVID-19 infection. Diabetes and hypertension have been identified as risk factors for oral LP development and COVID-19 mortality, and vitamin D has been found to modulate Th1 cells and regulate <italic toggle="yes">T</italic>-cell-mediated immune activity [<xref rid="B99-microorganisms-13-02129" ref-type="bibr">99</xref>]. However, further systematic studies are required to disentangle these associations from coincidental findings. The findings of autoimmune and chronic inflammatory skin diseases affected by COVID-19 infection are summarized in <xref rid="microorganisms-13-02129-t001" ref-type="table">Table 1</xref> and <xref rid="microorganisms-13-02129-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec11-microorganisms-13-02129"><title>11. COVID-19 and Vaccines</title><p>Emerging reports indicate cutaneous adverse events associated with COVID-19 vaccination including new-onset conditions and exacerbations of pre-existing dermatoses [<xref rid="B104-microorganisms-13-02129" ref-type="bibr">104</xref>]. Both mRNA and adenoviral vector SARS-CoV-2 vaccines activate innate immune sensors through intrinsic adjuvant activity, leading to the production of IFNs and pro-inflammatory cytokines [<xref rid="B105-microorganisms-13-02129" ref-type="bibr">105</xref>]. Adenoviral vectors activate Toll-like receptors (TLRs) 2 and 9, inducing cytokine expression through macrophage activation in the liver and spleen, while also eliciting robust CD4+ Th1 and humoral immune responses. In contrast, mRNA vaccines activate inflammation through TLRs 3, 7, and 8, with lipid nanoparticles (LNPs) exhibiting immunostimulatory properties even in the absence of mRNA cargo [<xref rid="B106-microorganisms-13-02129" ref-type="bibr">106</xref>]. Essentially, both vaccine platforms predominantly induce a Th1-skewed immune response, characterized by the increased production of TNF-&#945;, IFN-&#947;, and IL-2. In this context, this Th1-dominant environment necessitates the awareness of potential flares in immune-mediated skin conditions and connective tissue diseases, where Th1-mediated mechanisms are implicated in pathogenesis [<xref rid="B107-microorganisms-13-02129" ref-type="bibr">107</xref>].</p><p>Additionally, the incidence of de novo or relapsing autoimmune skin diseases appears higher following mRNA-based vaccines, potentially due to their elevated immunogenicity compared with viral vector and inactivated vaccines [<xref rid="B108-microorganisms-13-02129" ref-type="bibr">108</xref>]. In patients with hidradenitis suppurativa, a recent study has shown that those who received mRNA vaccines were 3.5 times as likely to develop flares following vaccination compared with patients who received non-mRNA vaccines, indicating that mRNA COVID-19 vaccines could be associated with hidradenitis suppurativa flares [<xref rid="B109-microorganisms-13-02129" ref-type="bibr">109</xref>]. Moreover, a study by J&#281;&#347;kowi-ak-Kossakowska et al. suggests that adenoviral vector vaccines may present fewer adverse effects, possibly due to the organism&#8217;s faster adaptation to this technology [<xref rid="B110-microorganisms-13-02129" ref-type="bibr">110</xref>]. On the other hand, inactivated viral vaccines, while weaker inducers of CD8+ T cell responses compared with mRNA and adenoviral vector vaccines, may therefore present a lower theoretical risk of triggering Th1-driven autoimmunity. Indeed, observational data suggest that inactivated vaccines are generally well-tolerated in patients with autoimmune and chronic inflammatory conditions. However, their immunogenicity is influenced by the choice of adjuvant, and large-scale comparative data in dermatologic autoimmune diseases remain scarce. This underscores the need for future studies to clarify their precise safety and efficacy profile in this population [<xref rid="B111-microorganisms-13-02129" ref-type="bibr">111</xref>].</p><p>Finally, a study by Sprow et al. found that most patients with autoimmune skin diseases effectively tolerated the COVID-19 vaccine. Although 14.8% of fully vaccinated participants reported exacerbations of autoimmune symptoms after vaccination, only 6.7% required an escalation in treatment, indicating that the overall safety and tolerability of the COVID-19 vaccine in this population remain high, despite the presence of underlying autoimmune conditions [<xref rid="B108-microorganisms-13-02129" ref-type="bibr">108</xref>]. Importantly, despite reports of cutaneous flares, the overall safety and tolerability of COVID-19 vaccines in patients with autoimmune skin diseases remain high, as the vast majority of individuals tolerated vaccination without clinically significant worsening of disease activity. These findings are summarized in <xref rid="microorganisms-13-02129-t002" ref-type="table">Table 2</xref>.</p></sec><sec sec-type="conclusions" id="sec12-microorganisms-13-02129"><title>12. Conclusions</title><p>Cutaneous manifestations of COVID-19 represent a heterogeneous spectrum, and their prognostic significance depends on the specific type of lesion rather than their mere presence. Early recognition of characteristic skin findings can enable dermatologists to contribute to timely COVID-19 diagnosis, particularly in patients with mild or asymptomatic infection. At present, the impact of pre-existing autoimmune skin diseases on COVID-19 severity and mortality remains uncertain, underscoring the importance of long-term monitoring to detect potential disease exacerbations or the development of new autoimmune connective tissue disorders. Vaccination with non-living platforms, including mRNA vaccines, is generally safe and effective in reducing severe outcomes, though a minority of patients may experience disease flares or new-onset autoimmune conditions. This highlights the need for individualized vaccination planning and close follow-up in patients with autoimmune skin diseases. Importantly, the lessons learned from the impact of COVID-19 on autoimmune skin disorders can serve as a framework for anticipating and mitigating similar complications in future pandemics. Strengthening surveillance systems, fostering multidisciplinary collaboration, and ensuring early dermatologic recognition may reduce morbidity and improve outcomes in comparable global health crises.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors have reviewed and edited the output and take full responsibility for the content of this publication.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.G.T. and A.I.L.; Methodology, E.R., K.P., E.T. and D.K.; Validation, G.S., A.G.T. and A.S.; Formal analysis, M.K., E.-K.B., R.S., P.I. and S.B.; Investigation, A.I.L., E.R., K.P. and E.T.; Data curation, A.I.L., E.R., K.P., E.T. and D.K.; Writing&#8212;original draft preparation, E.R., K.P. and E.T.; Writing&#8212;review and editing, A.I.L., E.R., K.P., E.T., D.K., M.K., E.-K.B., R.S., P.I., S.B., G.S., A.G.T. and A.S.; Visualization, E.R.; Supervision, A.G.T. and A.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-microorganisms-13-02129"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazdanpanah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>Autoimmune complications of COVID-19</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1002/jmv.27292</pub-id><pub-id pub-id-type="pmid">34427929</pub-id><pub-id pub-id-type="pmcid">PMC8661629</pub-id></element-citation></ref><ref id="B2-microorganisms-13-02129"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.Y.-T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.-I.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.-C.J.</given-names></name></person-group><article-title>Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study</article-title><source>eClinicalMedicine</source><year>2023</year><volume>56</volume><fpage>101783</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101783</pub-id><pub-id pub-id-type="pmid">36643619</pub-id><pub-id pub-id-type="pmcid">PMC9830133</pub-id></element-citation></ref><ref id="B3-microorganisms-13-02129"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ballard</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shuman</surname><given-names>V.L.</given-names></name></person-group><source>Hidradenitis Suppurativa</source><publisher-name>StatPearls</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><pub-id pub-id-type="pmid">30521288</pub-id></element-citation></ref><ref id="B4-microorganisms-13-02129"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sawalha</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name></person-group><article-title>COVID-19 and autoimmune diseases</article-title><source>Curr. Opin. Rheumatol.</source><year>2021</year><volume>33</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1097/BOR.0000000000000776</pub-id><pub-id pub-id-type="pmid">33332890</pub-id><pub-id pub-id-type="pmcid">PMC7880581</pub-id></element-citation></ref><ref id="B5-microorganisms-13-02129"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabat</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alavi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wortsman</surname><given-names>X.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>B.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szepietowski</surname><given-names>J.C.</given-names></name></person-group><article-title>Hidradenitis suppurativa</article-title><source>Lancet</source><year>2025</year><volume>405</volume><fpage>420</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)02475-9</pub-id><pub-id pub-id-type="pmid">39862870</pub-id></element-citation></ref><ref id="B6-microorganisms-13-02129"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlapbach</surname><given-names>C.</given-names></name><name name-style="western"><surname>H&#228;nni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yawalkar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hunger</surname><given-names>R.E.</given-names></name></person-group><article-title>Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa</article-title><source>J. Am. Acad. Dermatol.</source><year>2011</year><volume>65</volume><fpage>790</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2010.07.010</pub-id><pub-id pub-id-type="pmid">21641076</pub-id></element-citation></ref><ref id="B7-microorganisms-13-02129"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>R.</given-names></name><name name-style="western"><surname>McGarry</surname><given-names>T.</given-names></name><name name-style="western"><surname>Van Den Born</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adamzik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tobin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>B.</given-names></name></person-group><article-title>Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa</article-title><source>Br. J. Dermatol.</source><year>2015</year><volume>173</volume><fpage>1431</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1111/bjd.14075</pub-id><pub-id pub-id-type="pmid">26282467</pub-id></element-citation></ref><ref id="B8-microorganisms-13-02129"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witte-H&#228;ndel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsaousi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Irmer</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>M&#246;&#223;ner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shomroni</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lingner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Witte</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kunkel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salinas</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction</article-title><source>J. Investig. Dermatol.</source><year>2019</year><volume>139</volume><fpage>1294</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2018.11.018</pub-id><pub-id pub-id-type="pmid">30528824</pub-id></element-citation></ref><ref id="B9-microorganisms-13-02129"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liakou</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Tsantes</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Bompou</surname><given-names>E.-K.</given-names></name><name name-style="western"><surname>Kalamata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Agiasofitou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vladeni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dragoutsou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsante</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Ioannou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chatzidimitriou</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Risk Factors for Flares and New Lesions of Hidradenitis Suppurativa Following COVID-19 Disease: A Retrospective Cohort Study of 310 Patients in Greece</article-title><source>Microorganisms</source><year>2025</year><volume>13</volume><elocation-id>542</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms13030542</pub-id><pub-id pub-id-type="pmid">40142435</pub-id><pub-id pub-id-type="pmcid">PMC11945965</pub-id></element-citation></ref><ref id="B10-microorganisms-13-02129"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gracia-Ramos</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Martin-Nares</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Molina</surname><given-names>G.</given-names></name></person-group><article-title>New onset of autoimmune diseases following COVID-19 diagnosis</article-title><source>Cells</source><year>2021</year><volume>10</volume><elocation-id>3592</elocation-id><pub-id pub-id-type="doi">10.3390/cells10123592</pub-id><pub-id pub-id-type="pmid">34944099</pub-id><pub-id pub-id-type="pmcid">PMC8700122</pub-id></element-citation></ref><ref id="B11-microorganisms-13-02129"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>222</volume><fpage>746</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa363</pub-id><pub-id pub-id-type="pmid">32563194</pub-id><pub-id pub-id-type="pmcid">PMC7337752</pub-id></element-citation></ref><ref id="B12-microorganisms-13-02129"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smatti</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Cyprian</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Nasrallah</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Al Thani</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Almishal</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name></person-group><article-title>Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>762</elocation-id><pub-id pub-id-type="doi">10.3390/v11080762</pub-id><pub-id pub-id-type="pmid">31430946</pub-id><pub-id pub-id-type="pmcid">PMC6723519</pub-id></element-citation></ref><ref id="B13-microorganisms-13-02129"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abu Rached</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stockfleth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ocker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stranzenbach</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garcovich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hessam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bechara</surname><given-names>F.G.</given-names></name></person-group><article-title>Hidradenitis suppurativa in the SARS-CoV-2 pandemic: Investigation of trigger factors in a single center</article-title><source>J. Clin. Med.</source><year>2024</year><volume>13</volume><elocation-id>4074</elocation-id><pub-id pub-id-type="doi">10.3390/jcm13144074</pub-id><pub-id pub-id-type="pmid">39064114</pub-id><pub-id pub-id-type="pmcid">PMC11277551</pub-id></element-citation></ref><ref id="B14-microorganisms-13-02129"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torpey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nosrati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campton</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name></person-group><article-title>270 Impact of COVID-19 infection on hidradenitis suppurativa activity</article-title><source>J. Investig. Dermatol.</source><year>2022</year><volume>142</volume><fpage>S46</fpage><pub-id pub-id-type="doi">10.1016/j.jid.2022.05.277</pub-id></element-citation></ref><ref id="B15-microorganisms-13-02129"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name></person-group><article-title>The cytokine storm and COVID-19</article-title><source>J. Med. Virol.</source><year>2021</year><volume>93</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1002/jmv.26232</pub-id><pub-id pub-id-type="pmid">32592501</pub-id><pub-id pub-id-type="pmcid">PMC7361342</pub-id></element-citation></ref><ref id="B16-microorganisms-13-02129"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Kucharik</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Pourali</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Rajkumar</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yim</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>A.W.</given-names></name></person-group><article-title>The Use of biologics during the COVID-19</article-title><source>Pandemic Dermatol. Clin.</source><year>2021</year><volume>39</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.det.2021.05.010</pub-id><pub-id pub-id-type="pmid">34556244</pub-id><pub-id pub-id-type="pmcid">PMC8166518</pub-id></element-citation></ref><ref id="B17-microorganisms-13-02129"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimball</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Papp</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Zouboulis</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Kerdel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Forman</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>Two phase 3 trials of adalimumab for hidradenitis suppurativa</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504370</pub-id><pub-id pub-id-type="pmid">27518661</pub-id></element-citation></ref><ref id="B18-microorganisms-13-02129"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Rick</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hamzavi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>V.Y.</given-names></name></person-group><article-title>COVID-19 infection in hidradenitis suppurativa patients: A retrospective study</article-title><source>Ski. Appendage Disord.</source><year>2023</year><volume>9</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1159/000529462</pub-id><pub-id pub-id-type="pmcid">PMC10025363</pub-id><pub-id pub-id-type="pmid">37325275</pub-id></element-citation></ref><ref id="B19-microorganisms-13-02129"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liakou</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Kontochristopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marnelakis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tsantes</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Papadakis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alevizou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rotsiamis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rigopoulos</surname><given-names>D.</given-names></name></person-group><article-title>Thyroid disease and active smoking may be associated with more severe hidradenitis suppurativa: Data from a prospective cross sectional single-center study</article-title><source>Dermatology</source><year>2021</year><volume>237</volume><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1159/000508528</pub-id><pub-id pub-id-type="pmid">32966979</pub-id></element-citation></ref><ref id="B20-microorganisms-13-02129"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zouboulis</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Benhadou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Chandran</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Fabbrocini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Frew</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-L&#243;pez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Guillem</surname><given-names>P.</given-names></name><etal/></person-group><article-title>What causes hidradenitis suppurativa?&#8212;15 years after</article-title><source>Exp. Dermatol.</source><year>2020</year><volume>29</volume><fpage>1154</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1111/exd.14214</pub-id><pub-id pub-id-type="pmid">33058306</pub-id></element-citation></ref><ref id="B21-microorganisms-13-02129"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martora</surname><given-names>F.</given-names></name><name name-style="western"><surname>Picone</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fabbrocini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marasca</surname><given-names>C.</given-names></name></person-group><article-title>Hidradenitis suppurativa flares following COVID-19 vaccination: A case series</article-title><source>JAAD Case Rep.</source><year>2022</year><volume>23</volume><fpage>42</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.jdcr.2022.03.008</pub-id><pub-id pub-id-type="pmid">35308064</pub-id><pub-id pub-id-type="pmcid">PMC8916983</pub-id></element-citation></ref><ref id="B22-microorganisms-13-02129"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.P.</given-names></name></person-group><article-title>Response to Martora et al&#8217;s &#8220;Hidradenitis suppurativa flares following COVID-19 vaccination: A case series&#8221;</article-title><source>JAAD Case Rep.</source><year>2022</year><volume>25</volume><fpage>13</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jdcr.2022.05.005</pub-id><pub-id pub-id-type="pmid">35571456</pub-id><pub-id pub-id-type="pmcid">PMC9085457</pub-id></element-citation></ref><ref id="B23-microorganisms-13-02129"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pakhchanian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raiker</surname><given-names>R.</given-names></name><name name-style="western"><surname>DeYoung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name></person-group><article-title>Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa</article-title><source>Clin. Exp. Dermatol.</source><year>2022</year><volume>47</volume><fpage>1186</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1111/ced.15090</pub-id><pub-id pub-id-type="pmid">35179254</pub-id><pub-id pub-id-type="pmcid">PMC9111878</pub-id></element-citation></ref><ref id="B24-microorganisms-13-02129"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krueger</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Frew</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jemec</surname><given-names>G.B.E.</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bechara</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Navrazhina</surname><given-names>K.</given-names></name><name name-style="western"><surname>Prens</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reich</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Hidradenitis suppurativa: New insights into disease mechanisms and an evolving treatment landscape</article-title><source>Br. J. Dermatol.</source><year>2023</year><volume>190</volume><fpage>149</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1093/bjd/ljad345</pub-id><pub-id pub-id-type="pmid">37715694</pub-id></element-citation></ref><ref id="B25-microorganisms-13-02129"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bostan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jarbou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karaduman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gulseren</surname><given-names>D.</given-names></name><name name-style="western"><surname>Akdogan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yalici-Armagan</surname><given-names>B.</given-names></name></person-group><article-title>Impact of COVID-19 pandemic on hidradenitis suppurativa patients: A cross-sectional study from tertiary referral hospital</article-title><source>Dermatol. Pr. Concept.</source><year>2022</year><volume>12</volume><fpage>e2022192</fpage><pub-id pub-id-type="doi">10.5826/dpc.1204a192</pub-id><pub-id pub-id-type="pmid">36534566</pub-id><pub-id pub-id-type="pmcid">PMC9681235</pub-id></element-citation></ref><ref id="B26-microorganisms-13-02129"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naik</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Alhusayen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Frew</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guilbault</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hills</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kudlinski</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Lowes</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Marzano</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry</article-title><source>J. Am. Acad. Dermatol.</source><year>2021</year><volume>86</volume><fpage>249</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2021.09.016</pub-id><pub-id pub-id-type="pmid">34537252</pub-id><pub-id pub-id-type="pmcid">PMC8443529</pub-id></element-citation></ref><ref id="B27-microorganisms-13-02129"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowes</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Su&#225;rez-Fari&#241;as</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>J.G.</given-names></name></person-group><article-title>Immunology of psoriasis</article-title><source>Annu. Rev. Immunol.</source><year>2014</year><volume>32</volume><fpage>227</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120225</pub-id><pub-id pub-id-type="pmid">24655295</pub-id><pub-id pub-id-type="pmcid">PMC4229247</pub-id></element-citation></ref><ref id="B28-microorganisms-13-02129"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Man</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Or&#259;san</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hoteiuc</surname><given-names>O.-A.</given-names></name><name name-style="western"><surname>Ol&#259;nescu-Vaida-Voevod</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Mocan</surname><given-names>T.</given-names></name></person-group><article-title>Inflammation and psoriasis: A comprehensive review</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>16095</elocation-id><pub-id pub-id-type="doi">10.3390/ijms242216095</pub-id><pub-id pub-id-type="pmid">38003284</pub-id><pub-id pub-id-type="pmcid">PMC10671208</pub-id></element-citation></ref><ref id="B29-microorganisms-13-02129"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.-J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-Z.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J.-X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.-K.</given-names></name><etal/></person-group><article-title>Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: A cross-sectional survey</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>6331</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-54424-y</pub-id><pub-id pub-id-type="pmid">38491005</pub-id><pub-id pub-id-type="pmcid">PMC10943245</pub-id></element-citation></ref><ref id="B30-microorganisms-13-02129"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></element-citation></ref><ref id="B31-microorganisms-13-02129"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mungu&#237;a-Calzada</surname><given-names>P.</given-names></name><name name-style="western"><surname>Drake-Monfort</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armesto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cura</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>L&#243;pez-Sundh</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-L&#243;pez</surname><given-names>M.A.</given-names></name></person-group><article-title>Psoriasis flare after influenza vaccination in COVID-19 era: A report of four cases from a single center</article-title><source>Dermatol. Ther.</source><year>2020</year><volume>34</volume><fpage>e14684</fpage><pub-id pub-id-type="doi">10.1111/dth.14684</pub-id><pub-id pub-id-type="pmid">33331024</pub-id><pub-id pub-id-type="pmcid">PMC7883046</pub-id></element-citation></ref><ref id="B32-microorganisms-13-02129"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rendon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sch&#228;kel</surname><given-names>K.</given-names></name></person-group><article-title>Psoriasis pathogenesis and treatment</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>1475</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20061475</pub-id><pub-id pub-id-type="pmid">30909615</pub-id><pub-id pub-id-type="pmcid">PMC6471628</pub-id></element-citation></ref><ref id="B33-microorganisms-13-02129"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name></person-group><article-title>Biologics for psoriasis during the COVID-19 pandemic</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><elocation-id>759568</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.759568</pub-id><pub-id pub-id-type="pmid">34938746</pub-id><pub-id pub-id-type="pmcid">PMC8685238</pub-id></element-citation></ref><ref id="B34-microorganisms-13-02129"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campanati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diotallevi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Martina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Radi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Offidani</surname><given-names>A.</given-names></name></person-group><article-title>Treatment of moderate to severe psoriasis during the COVID-19 pandemic: Lessons learned and opportunities</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>2422</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11092422</pub-id><pub-id pub-id-type="pmid">35566548</pub-id><pub-id pub-id-type="pmcid">PMC9101352</pub-id></element-citation></ref><ref id="B35-microorganisms-13-02129"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Busquets</surname><given-names>A.C.</given-names></name></person-group><article-title>Psoriasis flares in patients with COVID-19 infection or vaccination: A case series</article-title><source>Cureus</source><year>2022</year><volume>14</volume><fpage>e25987</fpage><pub-id pub-id-type="doi">10.7759/cureus.25987</pub-id><pub-id pub-id-type="pmid">35855232</pub-id><pub-id pub-id-type="pmcid">PMC9286303</pub-id></element-citation></ref><ref id="B36-microorganisms-13-02129"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miladi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Janbakhsh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Babazadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aryanian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ebrahimpour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barary</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohseni Afshar</surname><given-names>Z.</given-names></name></person-group><article-title>Pustular psoriasis flare-up in a patient with COVID-19</article-title><source>J. Cosmet. Dermatol.</source><year>2021</year><volume>20</volume><fpage>3364</fpage><lpage>3368</lpage><pub-id pub-id-type="pmid">34619013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jocd.14508</pub-id><pub-id pub-id-type="pmcid">PMC8661619</pub-id></element-citation></ref><ref id="B37-microorganisms-13-02129"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibba</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gargiulo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pavia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Narcisi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Costanzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valenti</surname><given-names>M.</given-names></name></person-group><article-title>A severe psoriasis flare after COVID-19 treated with risankizumab: Complete skin clearance after 16 weeks</article-title><source>Dermatol. Rep.</source><year>2023</year><volume>16</volume><fpage>9722</fpage><pub-id pub-id-type="doi">10.4081/dr.2023.9722</pub-id><pub-id pub-id-type="pmcid">PMC11017708</pub-id><pub-id pub-id-type="pmid">38623366</pub-id></element-citation></ref><ref id="B38-microorganisms-13-02129"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tripathy</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kar</surname><given-names>B.R.</given-names></name></person-group><article-title>Guttate flare in a patient with chronic plaque psoriasis following COVID-19 infection: A case report</article-title><source>J. Cosmet. Dermatol.</source><year>2021</year><volume>20</volume><fpage>3064</fpage><pub-id pub-id-type="doi">10.1111/jocd.14396</pub-id><pub-id pub-id-type="pmid">34416089</pub-id><pub-id pub-id-type="pmcid">PMC8662084</pub-id></element-citation></ref><ref id="B39-microorganisms-13-02129"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janodia</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Kupetsky</surname><given-names>E.A.</given-names></name></person-group><article-title>Guttate psoriasis following COVID-19 infection</article-title><source>Cutis</source><year>2022</year><volume>109</volume><fpage>101</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.12788/cutis.0443</pub-id><pub-id pub-id-type="pmid">35659815</pub-id></element-citation></ref><ref id="B40-microorganisms-13-02129"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nogueira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vender</surname><given-names>R.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>T.</given-names></name></person-group><article-title>Psoriasis, biologic therapy, and the pandemic of the 21st century</article-title><source>Drugs Context</source><year>2020</year><volume>9</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.7573/dic.2020-4-10</pub-id><pub-id pub-id-type="pmcid">PMC7233295</pub-id><pub-id pub-id-type="pmid">32477419</pub-id></element-citation></ref><ref id="B41-microorganisms-13-02129"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loh</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>S.Y.C.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>C.C.</given-names></name></person-group><article-title>Teledermatology in the COVID-19 pandemic: A systematic review</article-title><source>JAAD Int.</source><year>2021</year><volume>5</volume><fpage>54</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.jdin.2021.07.007</pub-id><pub-id pub-id-type="pmid">34368789</pub-id><pub-id pub-id-type="pmcid">PMC8326016</pub-id></element-citation></ref><ref id="B42-microorganisms-13-02129"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filippi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Evangelista</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bardazzi</surname><given-names>F.</given-names></name></person-group><article-title>COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy</article-title><source>Dermatol. Ther.</source><year>2020</year><volume>33</volume><fpage>e13805</fpage><pub-id pub-id-type="doi">10.1111/dth.13805</pub-id><pub-id pub-id-type="pmid">32524715</pub-id><pub-id pub-id-type="pmcid">PMC7300534</pub-id></element-citation></ref><ref id="B43-microorganisms-13-02129"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henning</surname><given-names>M.A.S.</given-names></name><name name-style="western"><surname>Didriksen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ibler</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Ostrowski</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Erikstrup</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>K.</given-names></name><name name-style="western"><surname>S&#230;kmose</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Ullum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Th&#248;rner</surname><given-names>L.W.</given-names></name><etal/></person-group><article-title>The differentiating effect of COVID-19-associated stress on the morbidity of blood donors with symptoms of hidradenitis suppurativa, hyperhidrosis, or psoriasis</article-title><source>Qual. Life Res.</source><year>2023</year><volume>32</volume><fpage>2925</fpage><lpage>2937</lpage><pub-id pub-id-type="doi">10.1007/s11136-023-03448-4</pub-id><pub-id pub-id-type="pmid">37270451</pub-id><pub-id pub-id-type="pmcid">PMC10239219</pub-id></element-citation></ref><ref id="B44-microorganisms-13-02129"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yumeen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kroumpouzos</surname><given-names>G.</given-names></name></person-group><article-title>A critical review of COVID-19 course and vaccination in dermatology patients on immunomodulatory/biologic therapy: Recommendations should not differ between non-pregnant and pregnant individuals</article-title><source>Front. Med.</source><year>2023</year><volume>10</volume><elocation-id>1121025</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2023.1121025</pub-id><pub-id pub-id-type="pmcid">PMC10272467</pub-id><pub-id pub-id-type="pmid">37332768</pub-id></element-citation></ref><ref id="B45-microorganisms-13-02129"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liakou</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Tsantes</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Routsi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Agiasofitou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kalamata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bompou</surname><given-names>E.-K.</given-names></name><name name-style="western"><surname>Tsante</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Vladeni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chatzidimitriou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kotsafti</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Could Vaccination against COVID-19 Trigger Immune-Mediated Inflammatory Diseases?</article-title><source>J. Clin. Med.</source><year>2024</year><volume>13</volume><elocation-id>4617</elocation-id><pub-id pub-id-type="doi">10.3390/jcm13164617</pub-id><pub-id pub-id-type="pmid">39200759</pub-id><pub-id pub-id-type="pmcid">PMC11355883</pub-id></element-citation></ref><ref id="B46-microorganisms-13-02129"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freeman</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>T.H.</given-names></name></person-group><article-title>targeting the NLRP3 inflammasome in severe COVID-19</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>1518</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01518</pub-id><pub-id pub-id-type="pmid">32655582</pub-id><pub-id pub-id-type="pmcid">PMC7324760</pub-id></element-citation></ref><ref id="B47-microorganisms-13-02129"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddad</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kozman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kibbi</surname><given-names>A.-G.</given-names></name></person-group><article-title>Navigating patients with atopic dermatitis or chronic spontaneous urticaria during the COVID-19 pandemic</article-title><source>Front. Allergy</source><year>2022</year><volume>3</volume><elocation-id>809646</elocation-id><pub-id pub-id-type="doi">10.3389/falgy.2022.809646</pub-id><pub-id pub-id-type="pmid">36267954</pub-id><pub-id pub-id-type="pmcid">PMC9578570</pub-id></element-citation></ref><ref id="B48-microorganisms-13-02129"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buske-Kirschbaum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geiben</surname><given-names>A.</given-names></name><name name-style="western"><surname>H&#246;llig</surname><given-names>H.</given-names></name><name name-style="western"><surname>MorschhauSer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hellhammer</surname><given-names>D.</given-names></name></person-group><article-title>Altered responsiveness of the hypothalamus-pituitary-adrenal axis and the sympathetic adrenomedullary system to stress in patients with atopic dermatitis</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2002</year><volume>87</volume><fpage>4245</fpage><lpage>4251</lpage><pub-id pub-id-type="doi">10.1210/jc.2001-010872</pub-id><pub-id pub-id-type="pmid">12213879</pub-id></element-citation></ref><ref id="B49-microorganisms-13-02129"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Boguniewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>Q.A.</given-names></name></person-group><article-title>New insights into atopic dermatitis</article-title><source>J. Clin. Investig.</source><year>2004</year><volume>113</volume><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">14991059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI21060</pub-id><pub-id pub-id-type="pmcid">PMC351324</pub-id></element-citation></ref><ref id="B50-microorganisms-13-02129"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gittler</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Shemer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Su&#225;rez-Fari&#241;as</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuentes-Duculan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gulewicz</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.Q.</given-names></name><name name-style="western"><surname>Mitsui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>I.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>C.d.G.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis</article-title><source>J. Allergy Clin. Immunol.</source><year>2012</year><volume>130</volume><fpage>1344</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2012.07.012</pub-id><pub-id pub-id-type="pmid">22951056</pub-id><pub-id pub-id-type="pmcid">PMC3991245</pub-id></element-citation></ref><ref id="B51-microorganisms-13-02129"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijs</surname><given-names>L.E.M.</given-names></name><name name-style="western"><surname>Joustra</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Olydam</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Nijsten</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hijnen</surname><given-names>D.J.</given-names></name></person-group><article-title>COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: Real-world observational data</article-title><source>J. Eur. Acad. Dermatol. Venereol.</source><year>2021</year><volume>35</volume><fpage>pe173</fpage><pub-id pub-id-type="doi">10.1111/jdv.17025</pub-id><pub-id pub-id-type="pmid">33131098</pub-id></element-citation></ref><ref id="B52-microorganisms-13-02129"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miodo&#324;ska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bogacz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mr&#243;z</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mu&#263;ka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bo&#380;ek</surname><given-names>A.</given-names></name></person-group><article-title>The effect of SARS-CoV-2 virus infection on the course of atopic dermatitis in patients</article-title><source>Medicina</source><year>2021</year><volume>57</volume><elocation-id>521</elocation-id><pub-id pub-id-type="doi">10.3390/medicina57060521</pub-id><pub-id pub-id-type="pmid">34067403</pub-id><pub-id pub-id-type="pmcid">PMC8224743</pub-id></element-citation></ref><ref id="B53-microorganisms-13-02129"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ungar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Glickman</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Golant</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Dubin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marushchak</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gontzes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mikhaylov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>N.</given-names></name><etal/></person-group><article-title>COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with dupilumab</article-title><source>J. Allergy Clin. Immunol. Pr.</source><year>2021</year><volume>10</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2021.10.050</pub-id><pub-id pub-id-type="pmcid">PMC8558098</pub-id><pub-id pub-id-type="pmid">34737108</pub-id></element-citation></ref><ref id="B54-microorganisms-13-02129"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ehm</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vivirito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wende</surname><given-names>D.</given-names></name><name name-style="western"><surname>Batram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loser</surname><given-names>F.</given-names></name><name name-style="western"><surname>Menzer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roessler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Large cohort study shows increased risk of developing atopic dermatitis after COVID-19 disease</article-title><source>Allergy</source><year>2023</year><volume>79</volume><fpage>232</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1111/all.15827</pub-id><pub-id pub-id-type="pmid">37469301</pub-id></element-citation></ref><ref id="B55-microorganisms-13-02129"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pourani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ganji</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dashti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dadkhahfar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gheisari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdollahimajd</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dadras</surname><given-names>M.S.</given-names></name></person-group><article-title>Impact of COVID-19 pandemic on patients with atopic dermatitis</article-title><source>Actas Dermo-Sifiliograficas</source><year>2022</year><volume>113</volume><fpage>286</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.ad.2021.08.013</pub-id><pub-id pub-id-type="pmid">35153299</pub-id><pub-id pub-id-type="pmcid">PMC8824324</pub-id></element-citation></ref><ref id="B56-microorganisms-13-02129"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name></person-group><article-title>The correlation between corona virus disease 2019 and alopecia areata: A literature review</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1347311</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1347311</pub-id><pub-id pub-id-type="pmid">39021569</pub-id><pub-id pub-id-type="pmcid">PMC11251897</pub-id></element-citation></ref><ref id="B57-microorganisms-13-02129"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Poligone</surname><given-names>B.</given-names></name></person-group><article-title>Evaluation of the relationship between alopecia areata and viral antigen exposure</article-title><source>Am. J. Clin. Dermatol.</source><year>2017</year><volume>19</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/s40257-017-0312-y</pub-id><pub-id pub-id-type="pmid">28801732</pub-id></element-citation></ref><ref id="B58-microorganisms-13-02129"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cantisani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carlesimo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scarn&#242;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scali</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garelli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maxia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calvieri</surname><given-names>S.</given-names></name></person-group><article-title>Serum concentrations and IL-2, IL-6, IL-12 and TNF-&#945; in patients with alopecia areata</article-title><source>Int. J. Immunopathol. Pharmacol.</source><year>2012</year><volume>25</volume><fpage>781</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1177/039463201202500327</pub-id><pub-id pub-id-type="pmid">23058031</pub-id></element-citation></ref><ref id="B59-microorganisms-13-02129"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.-S.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name></person-group><article-title>Autoimmune and autoinflammatory connective tissue disorders following COVID-19</article-title><source>JAMA Netw. Open</source><year>2023</year><volume>6</volume><fpage>e2336120</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.36120</pub-id><pub-id pub-id-type="pmid">37801317</pub-id><pub-id pub-id-type="pmcid">PMC10559181</pub-id></element-citation></ref><ref id="B60-microorganisms-13-02129"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinaldi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Trink</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giuliani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>D.</given-names></name></person-group><article-title>Italian survey for the evaluation of the effects of coronavirus disease 2019 (COVID-19) pandemic on alopecia areata recurrence</article-title><source>Dermatol. Ther.</source><year>2021</year><volume>11</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1007/s13555-021-00498-9</pub-id><pub-id pub-id-type="pmid">33580408</pub-id><pub-id pub-id-type="pmcid">PMC7880634</pub-id></element-citation></ref><ref id="B61-microorganisms-13-02129"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Gwillim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ibler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Silverberg</surname><given-names>J.I.</given-names></name></person-group><article-title>Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis</article-title><source>J. Am. Acad. Dermatol.</source><year>2020</year><volume>82</volume><fpage>675</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2019.08.032</pub-id><pub-id pub-id-type="pmid">31437543</pub-id></element-citation></ref><ref id="B62-microorganisms-13-02129"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.-J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Yeom</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name></person-group><article-title>Risk of alopecia areata after COVID-19</article-title><source>JAMA Dermatol.</source><year>2024</year><volume>160</volume><fpage>232</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2023.5559</pub-id><pub-id pub-id-type="pmid">38198177</pub-id><pub-id pub-id-type="pmcid">PMC10782381</pub-id></element-citation></ref><ref id="B63-microorganisms-13-02129"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chrousos</surname><given-names>G.P.</given-names></name></person-group><article-title>The hypothalamic&#8211;pituitary&#8211;adrenal axis and immune-mediated inflammation</article-title><source>N. Engl. J. Med.</source><year>1995</year><volume>332</volume><fpage>1351</fpage><lpage>1363</lpage><pub-id pub-id-type="pmid">7715646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199505183322008</pub-id></element-citation></ref><ref id="B64-microorganisms-13-02129"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucchese</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fusco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donnarumma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Borgia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baroni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petruzzi</surname><given-names>M.</given-names></name></person-group><article-title>COVID 19 and bullous pemphigoid: A hypothesis for a causal link</article-title><source>J. Biol. Regul. Homeost. Agents</source><year>2022</year><volume>36</volume><fpage>19</fpage><lpage>25</lpage></element-citation></ref><ref id="B65-microorganisms-13-02129"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pastukhova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ghazawi</surname><given-names>F.M.</given-names></name></person-group><article-title>New-onset of pemphigus following COVID-19 infection: A case report</article-title><source>SAGE Open Med. Case Rep.</source><year>2024</year><volume>12</volume><fpage>2050313X241231423</fpage><pub-id pub-id-type="doi">10.1177/2050313X241231423</pub-id><pub-id pub-id-type="pmcid">PMC10874115</pub-id><pub-id pub-id-type="pmid">38371950</pub-id></element-citation></ref><ref id="B66-microorganisms-13-02129"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghalamkarpour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pourani</surname><given-names>M.R.</given-names></name></person-group><article-title>Aggressive course of pemphigus vulgaris followingCOVID-19 infection</article-title><source>Dermatol. Ther.</source><year>2020</year><volume>33</volume><fpage>e14398</fpage><pub-id pub-id-type="doi">10.1111/dth.14398</pub-id><pub-id pub-id-type="pmid">33040414</pub-id><pub-id pub-id-type="pmcid">PMC7646050</pub-id></element-citation></ref><ref id="B67-microorganisms-13-02129"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kridin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zirpel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akyuz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thaci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>R.J.</given-names></name></person-group><article-title>COVID-19 infection is associated with an elevated risk for autoimmune blistering diseases while COVID-19 vaccination decreases the risk: A large-scale population-based cohort study of 112 million individuals</article-title><source>J. Am. Acad. Dermatol.</source><year>2024</year><volume>92</volume><fpage>452</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2024.10.063</pub-id><pub-id pub-id-type="pmid">39521140</pub-id></element-citation></ref><ref id="B68-microorganisms-13-02129"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kridin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schonmann</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>O.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A.D.</given-names></name></person-group><article-title>The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study</article-title><source>J. Am. Acad. Dermatol.</source><year>2021</year><volume>85</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2021.02.087</pub-id><pub-id pub-id-type="pmid">33744354</pub-id><pub-id pub-id-type="pmcid">PMC7968167</pub-id></element-citation></ref><ref id="B69-microorganisms-13-02129"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmas</surname><given-names>&#214;.F.</given-names></name><name name-style="western"><surname>Demirba&#351;</surname><given-names>A.</given-names></name><name name-style="western"><surname>T&#252;rsen</surname><given-names>&#220;.</given-names></name><name name-style="western"><surname>Atasoy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lotti</surname><given-names>T.</given-names></name></person-group><article-title>Pemphigus and COVID-19: Critical overview of management with a focus on treatment choice</article-title><source>Dermatol. Ther.</source><year>2020</year><volume>33</volume><fpage>e14265</fpage><pub-id pub-id-type="doi">10.1111/dth.14265</pub-id><pub-id pub-id-type="pmid">32882079</pub-id></element-citation></ref><ref id="B70-microorganisms-13-02129"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbhaiya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Costenbader</surname><given-names>K.H.</given-names></name></person-group><article-title>Environmental exposures and the development of systemic lupus erythematosus</article-title><source>Curr. Opin. Rheumatol.</source><year>2016</year><volume>28</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1097/BOR.0000000000000318</pub-id><pub-id pub-id-type="pmid">27428889</pub-id><pub-id pub-id-type="pmcid">PMC4965307</pub-id></element-citation></ref><ref id="B71-microorganisms-13-02129"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gazzaruso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coppola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naldani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gallotti</surname><given-names>P.</given-names></name></person-group><article-title>High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia</article-title><source>Clin. Rheumatol.</source><year>2020</year><volume>39</volume><fpage>2095</fpage><lpage>2097</lpage><pub-id pub-id-type="doi">10.1007/s10067-020-05180-7</pub-id><pub-id pub-id-type="pmid">32462425</pub-id><pub-id pub-id-type="pmcid">PMC7251560</pub-id></element-citation></ref><ref id="B72-microorganisms-13-02129"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujii</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yuba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suga</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hiraoka</surname><given-names>N.</given-names></name></person-group><article-title>High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: A case-based review: High levels of anti-SSA/Ro antibodies in COVID-19</article-title><source>Clin. Rheumatol.</source><year>2020</year><volume>39</volume><fpage>3171</fpage><lpage>3175</lpage><pub-id pub-id-type="doi">10.1007/s10067-020-05359-y</pub-id><pub-id pub-id-type="pmid">32844364</pub-id><pub-id pub-id-type="pmcid">PMC7447083</pub-id></element-citation></ref><ref id="B73-microorganisms-13-02129"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drenovska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shahid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mateeva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vassileva</surname><given-names>S.</given-names></name></person-group><article-title>Case Report: Rowell Syndrome&#8211;Like Flare of Cutaneous Lupus Erythematosus Following COVID-19</article-title><source>Infection. Front. Med.</source><year>2022</year><volume>9</volume><fpage>815743</fpage><pub-id pub-id-type="doi">10.3389/fmed.2022.815743</pub-id><pub-id pub-id-type="pmid">35237629</pub-id><pub-id pub-id-type="pmcid">PMC8882728</pub-id></element-citation></ref><ref id="B74-microorganisms-13-02129"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abuhammad</surname><given-names>A.</given-names></name><name name-style="western"><surname>AbuKhalaf</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>AbuKhalaf</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Janem</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Attawna</surname><given-names>S.I.Y.</given-names></name></person-group><article-title>Lupus panniculitis as the initial presentation of systemic lupus erythematosus triggered by COVID-19 infection: Case report and literature review</article-title><source>Oxf. Med. Case Rep.</source><year>2023</year><volume>2023</volume><fpage>436</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1093/omcr/omad129</pub-id><pub-id pub-id-type="pmid">38033407</pub-id><pub-id pub-id-type="pmcid">PMC10686000</pub-id></element-citation></ref><ref id="B75-microorganisms-13-02129"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matucci-Cerinic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bruni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Allanore</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Clementi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dagna</surname><given-names>L.</given-names></name><name name-style="western"><surname>Damjanov</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>de Paulis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Denton</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Distler</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management</article-title><source>Ann. Rheum. Dis.</source><year>2020</year><volume>79</volume><fpage>724</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2020-217407</pub-id><pub-id pub-id-type="pmid">32349982</pub-id></element-citation></ref><ref id="B76-microorganisms-13-02129"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cond&#233;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Atakla</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Garba</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Garba</surname><given-names>I.</given-names></name></person-group><article-title>COVID-19 infection during autoimmune disease: Study of 2 cases in Republic of Guinea</article-title><source>Pan Afr. Med. J.</source><year>2020</year><volume>35</volume><issue>(Suppl. 2)</issue><fpage>96</fpage><pub-id pub-id-type="doi">10.11604/pamj.supp.2020.35.2.24616</pub-id><pub-id pub-id-type="pmcid">PMC7875779</pub-id><pub-id pub-id-type="pmid">33623620</pub-id></element-citation></ref><ref id="B77-microorganisms-13-02129"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peach</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rutter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lanyon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grainge</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aston</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bythell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>F.</given-names></name></person-group><article-title>Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic</article-title><source>Rheumatology</source><year>2020</year><volume>60</volume><fpage>1902</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keaa855</pub-id><pub-id pub-id-type="pmcid">PMC7798585</pub-id><pub-id pub-id-type="pmid">33271595</pub-id></element-citation></ref><ref id="B78-microorganisms-13-02129"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nagarajah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>S.</given-names></name></person-group><article-title>Systemic sclerosis following COVID-19 infection with recurrent corticosteroid-induced scleroderma renal crisis</article-title><source>BMJ Case Rep.</source><year>2023</year><volume>16</volume><fpage>e253735</fpage><pub-id pub-id-type="doi">10.1136/bcr-2022-253735</pub-id><pub-id pub-id-type="pmcid">PMC10030551</pub-id><pub-id pub-id-type="pmid">36931690</pub-id></element-citation></ref><ref id="B79-microorganisms-13-02129"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orlandi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lepri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bruni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bartoloni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zammarchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cometi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guiducci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matucci-Cerinic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bellando-Randone</surname><given-names>S.</given-names></name></person-group><article-title>The systemic sclerosis patient in the COVID-19 era: The challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress</article-title><source>Clin. Rheumatol.</source><year>2020</year><volume>39</volume><fpage>2043</fpage><lpage>2047</lpage><pub-id pub-id-type="doi">10.1007/s10067-020-05193-2</pub-id><pub-id pub-id-type="pmid">32514674</pub-id><pub-id pub-id-type="pmcid">PMC7276334</pub-id></element-citation></ref><ref id="B80-microorganisms-13-02129"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sasajima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Temmoku</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Asano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohira</surname><given-names>H.</given-names></name><etal/></person-group><article-title>New-onset dermatomyositis following COVID-19: A case report</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1002329</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1002329</pub-id><pub-id pub-id-type="pmid">36353621</pub-id><pub-id pub-id-type="pmcid">PMC9637802</pub-id></element-citation></ref><ref id="B81-microorganisms-13-02129"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albakri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Subki</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Albeity</surname><given-names>A.</given-names></name><name name-style="western"><surname>Halabi</surname><given-names>H.</given-names></name></person-group><article-title>Dermatomyositis flare after a COVID-19 infection successfully treated with rituximab: A case report and literature review</article-title><source>J. Inflamm. Res.</source><year>2022</year><volume>15</volume><fpage>6047</fpage><lpage>6053</lpage><pub-id pub-id-type="doi">10.2147/JIR.S369477</pub-id><pub-id pub-id-type="pmid">36348728</pub-id><pub-id pub-id-type="pmcid">PMC9637344</pub-id></element-citation></ref><ref id="B82-microorganisms-13-02129"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Beltagi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Bediwy</surname><given-names>A.S.</given-names></name></person-group><article-title>COVID-19 disease and autoimmune disorders: A mutual pathway</article-title><source>World J. Methodol.</source><year>2022</year><volume>12</volume><fpage>200</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.5662/wjm.v12.i4.200</pub-id><pub-id pub-id-type="pmid">36159097</pub-id><pub-id pub-id-type="pmcid">PMC9350728</pub-id></element-citation></ref><ref id="B83-microorganisms-13-02129"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name></person-group><article-title>Management of dermatomyositis patients amidst the COVID-19 pandemic: Two case reports</article-title><source>Medicine</source><year>2022</year><volume>101</volume><fpage>e30634</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000030634</pub-id><pub-id pub-id-type="pmid">36197238</pub-id><pub-id pub-id-type="pmcid">PMC9509195</pub-id></element-citation></ref><ref id="B84-microorganisms-13-02129"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorouhi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Davari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fazel</surname><given-names>N.</given-names></name></person-group><article-title>Cutaneous and mucosal lichen planus: A comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis</article-title><source>Sci. World J.</source><year>2014</year><volume>2014</volume><fpage>742826</fpage><pub-id pub-id-type="doi">10.1155/2014/742826</pub-id><pub-id pub-id-type="pmcid">PMC3929580</pub-id><pub-id pub-id-type="pmid">24672362</pub-id></element-citation></ref><ref id="B85-microorganisms-13-02129"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ujiie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rosmarin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sch&#246;n</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>St&#228;nder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Metz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thaci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Unmet medical needs in chronic, non-communicable inflammatory skin diseases</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><elocation-id>875492</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2022.875492</pub-id><pub-id pub-id-type="pmcid">PMC9218547</pub-id><pub-id pub-id-type="pmid">35755063</pub-id></element-citation></ref><ref id="B86-microorganisms-13-02129"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussein</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Rahal</surname><given-names>E.A.</given-names></name></person-group><article-title>The role of viral infections in the development of autoimmune diseases</article-title><source>Crit. Rev. Microbiol.</source><year>2019</year><volume>45</volume><fpage>394</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1080/1040841X.2019.1614904</pub-id><pub-id pub-id-type="pmid">31145640</pub-id></element-citation></ref><ref id="B87-microorganisms-13-02129"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiohara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moriya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Narimatsu</surname><given-names>H.</given-names></name></person-group><article-title>Lichenoid tissue reaction induced by local transfer of ia-reactive t-cell clones</article-title><source>J. Investig. Dermatol.</source><year>1986</year><volume>87</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12523539</pub-id><pub-id pub-id-type="pmid">2941489</pub-id></element-citation></ref><ref id="B88-microorganisms-13-02129"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugerman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Satterwhite</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bigby</surname><given-names>M.</given-names></name></person-group><article-title>Autocytotoxic T-cell clones in lichen planus</article-title><source>Br. J. Dermatol.</source><year>2000</year><volume>142</volume><fpage>449</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2000.03355.x</pub-id><pub-id pub-id-type="pmid">10735949</pub-id></element-citation></ref><ref id="B89-microorganisms-13-02129"><label>89.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Shiohara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moriya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>M.</given-names></name></person-group><article-title>Induction and Control of Lichenoid Tissue Reactions</article-title><source>Springer Seminars in Immunopathology</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>1992</year><volume>Volume 13</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00200535</pub-id><pub-id pub-id-type="pmid">1411903</pub-id></element-citation></ref><ref id="B90-microorganisms-13-02129"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Requena</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kutzner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Escalonilla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rohwedder</surname><given-names>A.</given-names></name></person-group><article-title>Cutaneous reactions at sites of herpes zoster scars: An expanded spectrum</article-title><source>Br. J. Dermatol.</source><year>1998</year><volume>138</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.1998.02045.x</pub-id><pub-id pub-id-type="pmid">9536241</pub-id></element-citation></ref><ref id="B91-microorganisms-13-02129"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizukawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Horie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shiohara</surname><given-names>T.</given-names></name></person-group><article-title>Detection of varicella-zoster virus antigens in lesional skin of zosteriform lichen planus but not in that of linear lichen planus</article-title><source>Dermatology</source><year>2012</year><volume>225</volume><fpage>22</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1159/000339771</pub-id><pub-id pub-id-type="pmid">22813536</pub-id></element-citation></ref><ref id="B92-microorganisms-13-02129"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-Guimaraens</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dominguez-Santas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suarez-Valle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandez-Nieto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jimenez-Cauhe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ballester</surname><given-names>A.</given-names></name></person-group><article-title>Annular lichen planus associated with coronavirus SARSCoV-2 disease (COVID-19)</article-title><source>Int. J. Dermatol.</source><year>2021</year><volume>60</volume><fpage>246</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/ijd.15338</pub-id><pub-id pub-id-type="pmid">33320353</pub-id></element-citation></ref><ref id="B93-microorganisms-13-02129"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paolino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rongioletti</surname><given-names>F.</given-names></name></person-group><article-title>Palmoplantar lichenoid drug eruption following the administration of Pfizer-BioNTech COVID-19 vaccine</article-title><source>JAAD Case Rep.</source><year>2022</year><volume>21</volume><fpage>182</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.jdcr.2022.01.014</pub-id><pub-id pub-id-type="pmid">35097176</pub-id><pub-id pub-id-type="pmcid">PMC8785366</pub-id></element-citation></ref><ref id="B94-microorganisms-13-02129"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zengarini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Piraccini</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>La Placa</surname><given-names>M.</given-names></name></person-group><article-title>Lichen Ruber planus occurring after SARS-CoV-2 vaccination</article-title><source>Dermatol. Ther.</source><year>2022</year><volume>35</volume><fpage>e15389</fpage><pub-id pub-id-type="pmid">35174595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dth.15389</pub-id><pub-id pub-id-type="pmcid">PMC9111831</pub-id></element-citation></ref><ref id="B95-microorganisms-13-02129"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fidan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Koyuncu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akin</surname><given-names>O.</given-names></name></person-group><article-title>Oral lesions in COVID 19 positive patients</article-title><source>Am. J. Otolaryngol.</source><year>2021</year><volume>42</volume><fpage>102905</fpage><pub-id pub-id-type="doi">10.1016/j.amjoto.2021.102905</pub-id><pub-id pub-id-type="pmid">33497914</pub-id><pub-id pub-id-type="pmcid">PMC7826088</pub-id></element-citation></ref><ref id="B96-microorganisms-13-02129"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saleh</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shawky</surname><given-names>E.</given-names></name><name name-style="western"><surname>Halim</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Ata</surname><given-names>F.</given-names></name></person-group><article-title>Oral lichen planus after COVID-19, a case report</article-title><source>Ann. Med. Surg.</source><year>2021</year><volume>72</volume><fpage>103051</fpage><pub-id pub-id-type="doi">10.1016/j.amsu.2021.103051</pub-id><pub-id pub-id-type="pmcid">PMC8580550</pub-id><pub-id pub-id-type="pmid">34786190</pub-id></element-citation></ref><ref id="B97-microorganisms-13-02129"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgos-Blasco</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fernandez-Nieto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Selda-Enriquez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Melian-Olivera</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Perosanz-Lobo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dominguez-Santas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alonso-Castro</surname><given-names>L.</given-names></name></person-group><article-title>COVID-19: A possible trigger for oral lichen planus?</article-title><source>Int. J. Dermatol.</source><year>2021</year><volume>60</volume><fpage>882</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1111/ijd.15529</pub-id><pub-id pub-id-type="pmid">33686658</pub-id><pub-id pub-id-type="pmcid">PMC8250697</pub-id></element-citation></ref><ref id="B98-microorganisms-13-02129"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gimeno Castillo</surname><given-names>J.</given-names></name><name name-style="western"><surname>de la Torre Gomar</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Saenz Aguirre</surname><given-names>A.</given-names></name></person-group><article-title>Lichen Planus after SARS-CoV-2 infection treated with Lopinavir/Ritonavir</article-title><source>Med. Cl&#237;n.</source><year>2021</year><volume>156</volume><fpage>468</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.medcli.2020.12.014</pub-id><pub-id pub-id-type="pmcid">PMC7980180</pub-id><pub-id pub-id-type="pmid">33778159</pub-id></element-citation></ref><ref id="B99-microorganisms-13-02129"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Batra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>K.</given-names></name><name name-style="western"><surname>Talwar</surname><given-names>A.</given-names></name></person-group><article-title>Rise and exacerbation of oral lichen planus in the background of SARS-CoV-2 infection</article-title><source>Med. Hypotheses</source><year>2021</year><volume>156</volume><fpage>110681</fpage><pub-id pub-id-type="doi">10.1016/j.mehy.2021.110681</pub-id><pub-id pub-id-type="pmid">34601231</pub-id><pub-id pub-id-type="pmcid">PMC8478127</pub-id></element-citation></ref><ref id="B100-microorganisms-13-02129"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gisondi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bellinato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Girolomoni</surname><given-names>G.</given-names></name></person-group><article-title>Skin adverse reactions to SARS-CoV-2 vaccination: A relevant responsibility issue for dermatologists</article-title><source>J. Eur. Acad. Dermatol. Venereol.</source><year>2022</year><volume>36</volume><fpage>165</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1111/jdv.17854</pub-id><pub-id pub-id-type="pmid">35037307</pub-id></element-citation></ref><ref id="B101-microorganisms-13-02129"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>High Expression of ACE2 on keratinocytes reveals skin as a potential target for SARS-CoV-19</article-title><source>J. Investig.</source><year>2021</year><volume>141</volume><fpage>206</fpage><lpage>209.e1</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2020.05.087</pub-id><pub-id pub-id-type="pmcid">PMC7245327</pub-id><pub-id pub-id-type="pmid">32454066</pub-id></element-citation></ref><ref id="B102-microorganisms-13-02129"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motahari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Rasi</surname><given-names>A.</given-names></name></person-group><article-title>Role of vitamin d and vitamin d receptor in oral lichen planus: A systematic review</article-title><source>Ethiop. J. Heal. Sci.</source><year>2020</year><volume>30</volume><fpage>615</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.4314/ejhs.v30i4.17</pub-id><pub-id pub-id-type="pmcid">PMC8054464</pub-id><pub-id pub-id-type="pmid">33897222</pub-id></element-citation></ref><ref id="B103-microorganisms-13-02129"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kiran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Panigrahi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thachil</surname><given-names>J.M.</given-names></name></person-group><article-title>Oral lichen planus and associated comorbidities: An approach to holistic health</article-title><source>J. Fam. Med. Prim. Care</source><year>2019</year><volume>8</volume><fpage>3504</fpage><lpage>3517</lpage><pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_749_19</pub-id><pub-id pub-id-type="pmcid">PMC6881968</pub-id><pub-id pub-id-type="pmid">31803644</pub-id></element-citation></ref><ref id="B104-microorganisms-13-02129"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niebel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wilhelmi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ziob</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilsmann-Theis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bieber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Braegelmann</surname><given-names>C.</given-names></name></person-group><article-title>Cutaneous adverse reactions to COVID-19 vaccines: Insights from an immuno-dermatological perspective</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>944</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9090944</pub-id><pub-id pub-id-type="pmid">34579181</pub-id><pub-id pub-id-type="pmcid">PMC8470727</pub-id></element-citation></ref><ref id="B105-microorganisms-13-02129"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teijaro</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>D.L.</given-names></name></person-group><article-title>COVID-19 vaccines: Modes of immune activation and future challenges</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00526-x</pub-id><pub-id pub-id-type="pmid">33674759</pub-id><pub-id pub-id-type="pmcid">PMC7934118</pub-id></element-citation></ref><ref id="B106-microorganisms-13-02129"><label>106.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>B.</given-names></name></person-group><article-title>Adenoviral Vector-Based Vaccines and Gene Therapies: Current Status and Future Prospects</article-title><source>Adenoviruses</source><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2019</year></element-citation></ref><ref id="B107-microorganisms-13-02129"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coondoo</surname><given-names>A.</given-names></name></person-group><article-title>The role of cytokines in the pathomechanism of cutaneous disorders</article-title><source>Indian J. Dermatol.</source><year>2012</year><volume>57</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.4103/0019-5154.94272</pub-id><pub-id pub-id-type="pmid">22615502</pub-id><pub-id pub-id-type="pmcid">PMC3352652</pub-id></element-citation></ref><ref id="B108-microorganisms-13-02129"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sprow</surname><given-names>G.</given-names></name><name name-style="western"><surname>Afarideh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Keyes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grinnell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Concha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Werth</surname><given-names>V.P.</given-names></name></person-group><article-title>Autoimmune skin disease exacerbations following COVID-19 vaccination</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>899526</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.899526</pub-id><pub-id pub-id-type="pmid">35693768</pub-id><pub-id pub-id-type="pmcid">PMC9186119</pub-id></element-citation></ref><ref id="B109-microorganisms-13-02129"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liakou</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Tsantes</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Kalamata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsamtsouri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Agiasofitou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vladeni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dragoutsou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bompou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsante</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Chatzidimitriou</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Flares and new related lesions of Hidradenitis Suppurativa following COVID-19 vaccination: A retrospective cohort study of 250 patients in Greece</article-title><source>J. Eur. Acad. Dermatol. Venereol.</source><year>2024</year><volume>38</volume><fpage>e648</fpage><lpage>e650</lpage><pub-id pub-id-type="doi">10.1111/jdv.19968</pub-id><pub-id pub-id-type="pmid">38511998</pub-id></element-citation></ref><ref id="B110-microorganisms-13-02129"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#281;&#347;kowiak-Kossakowska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nowotarska</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grosman-Dziewiszek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Szel&#261;g</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wiatrak</surname><given-names>B.</given-names></name></person-group><article-title>Impact of comorbidities and skin diseases on post-vaccination reactions: A study on COVID-19 vaccinations in poland</article-title><source>J. Clin. Med.</source><year>2024</year><volume>13</volume><elocation-id>6173</elocation-id><pub-id pub-id-type="doi">10.3390/jcm13206173</pub-id><pub-id pub-id-type="pmid">39458123</pub-id><pub-id pub-id-type="pmcid">PMC11508506</pub-id></element-citation></ref><ref id="B111-microorganisms-13-02129"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeyanathan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smaill</surname><given-names>F.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lichty</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z.</given-names></name></person-group><article-title>Immunological considerations for COVID-19 vaccine strategies</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>615</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00434-6</pub-id><pub-id pub-id-type="pmid">32887954</pub-id><pub-id pub-id-type="pmcid">PMC7472682</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="microorganisms-13-02129-f001" orientation="portrait"><label>Figure 1</label><caption><p>Potential mechanisms linking COVID-19 infection with the development or exacerbation of dermatologic autoimmune and inflammatory skin diseases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="microorganisms-13-02129-g001.jpg"/></fig><table-wrap position="float" id="microorganisms-13-02129-t001" orientation="portrait"><object-id pub-id-type="pii">microorganisms-13-02129-t001_Table 1</object-id><label>Table 1</label><caption><p>Autoimmune and chronic inflammatory skin diseases affected by COVID-19 infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Impact of COVID-19 Infection</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proposed Mechanisms</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psoriasis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New onset and exacerbation reported</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-17, IL-23, TNF-a axis dysregulation; stress-induced immune dysregulation, ACE2 mediated inflammation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exacerbations more common with prior history; may be influenced by treatments</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hidradenitis Suppurativa</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exacerbation common</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-17, IL-23, TNF-a axis dysregulation, stress, cytokine storm</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease flares may be related to COVID-induced cytokine storm</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atopic Dermatitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New onset and flare-ups</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Th2 dominance; impaired skin barrier, psychological stress</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe flares reported in previously well-controlled cases</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alopecia Areata</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New onset or exacerbation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic inflammation, immune dysregulation, psychological stress</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onset often 1&#8211;2 months post-infection; relapse rate higher than controls</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pemphigus and Bullous Pemphigoid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flare-ups or new onset</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hyperinflammatory immune activation, autoantigen exposure</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunosuppressants may increase infection risk/severity</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cutaneous Lupus Erythematosus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exacerbation or rare new onset</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral-triggered immune activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited to case reports</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic Sclerosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New onset; possible ILD worsening</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spike-protein-induced fibrosis; autoantibody activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ILD may mask or worsen COVID-related respiratory symptoms</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dermatomyositis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease onset and exacerbation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune cascade activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flare-ups also after mild cases</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lichen Planus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sporadic new onset</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD8+ T-cell activation, Th17 involvement, molecular mimicry</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D deficiency, HTN, diabetes may be co-factors</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: HTN, hypertension, ILD, interstitial lung disease, IL, interleukin, TNF, tumor necrosis factor, ACE, angiotensin-converting enzyme.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="microorganisms-13-02129-t002" orientation="portrait"><object-id pub-id-type="pii">microorganisms-13-02129-t002_Table 2</object-id><label>Table 2</label><caption><p>Autoimmune skin diseases and COVID-19 vaccination.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Platform</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Immune Activation</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dominant Cytokines/Immune Responses</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cutaneous Adverse Events</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune Flare Risk</th></tr></thead><tbody><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>mRNA Vaccines</bold>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Activation of TLRs 3, 7, 8 via mRNA<break/><break/>Intrinsic adjuvanticity of lipid nanoparticles <break/><break/>Type I IFN production</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Th1 polarization: &#8593; TNF-&#945;, &#8593; IFN-&#947;, &#8593; IL-2<break/><break/>Robust CD8+ T-cell activation</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher prevalence of psoriasis, lichen planus, lupus flares<break/><break/>Localized erythema</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevated due to Th1 skewing<break/><break/>Strong immunogenicity linked to higher autoimmune risk</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Adenoviral Vector Vaccines</bold>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TLRs 2, 9 activation<break/><break/>Macrophage activation in liver/spleen<break/><break/>Stimulation of CD4+ Th1 and antibody production</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Th1-dominant: &#8593; TNF-&#945;, &#8593; IFN-&#947;, &#8593; IL-2<break/><break/>Moderate CD8+ T-cell activation</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower CAE incidence<break/><break/>Dermatitis, mild urticaria</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced due to faster immune adaptation<break/><break/>Milder flares compared to mRNA vaccines</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Inactivated Virus Vaccines</bold>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Weak innate activation via adjuvants<break/><break/>Dependent on antigen formulation</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited Th1 polarization<break/><break/>Weak CD8+ T-cell activation</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimal CAEs<break/><break/>Mild transient rashes</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower risk due to weaker immune activation<break/><break/>Rare autoimmune flare cases</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ASD, autoimmune skin diseases, TNF-&#945;, tumor necrosis factor-a, IFN, interferon, TLR, Toll-like receptors, CAE, cutaneous adverse events. &#8593;, increase</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>